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Castration resistant prostate cancer (CRPC) is an androgen dependent disease driven by the 
intratumoural metabolism of adrenal androgen precursors to potent androgens. The alternative 5α-
dione pathway converts the adrenal steroids DHEA and androstenedione (A4) to the potent 
androgen DHT, while the recently identified 11β-hydroxyandrostenedione (11OHA4) pathway 
converts the adrenal steroid 11OHA4 into the potent androgens 11-ketotestosterone (11KT) and 
11-ketodihydrotestosterone (11KDHT).  
Two 17β-hydroxysteroid dehydrogenase (17βHSD) enzymes catalyse vital reactions in both 
pathways. 17βHSD2 catalyses the oxidation of androgens to their less active form, while 
17βHSD5, which is better known as AKR1C3, catalyses the reduction of weak androgens to more 
potent androgens. The relative activity and expression levels of these enzymes are therefore vital 
in regulating the amount of active androgen produced. The aim of this project was to characterise 
the activity of 17βHSD2 towards 11-oxygenated steroids from the 11OHA4 pathway and to 
investigate the effect of different ratios of AKR1C3 and 17βHSD2 on the flux through the 
alternative 5α-dione and 11OHA4 pathways.  
17βHSD2 activity towards the 11-oxygenated steroids 11KT and 11KDHT were characterised for 
the first time using HEK293 cells transiently transfected to express 17βHSD2. The results showed 
that 17βHSD2 efficiently catalysed the conversion of 11KT and 11KDHT to their respective 
products. Interestingly the catalytic efficiency tended to be higher for the conversion of testosterone 
(T) to A4 than the conversion of 11KT to 11KA4, although this difference was not significant. 
The effect of increasing ratios of AKR1C3:17βHSD2, which occur during CRPC, were 
subsequently investigated. HEK293 cells, which do not endogenously express either AKR1C3 or 
17βHSD2, were transiently transfected to express each enzyme, and the cells subsequently 
combined in different ratios. PC3 cells, which endogenously express 17βHSD2, were transfected 
with increasing amounts of AKR1C3 to obtain different AKR1C3:17βHSD2 ratios.  
Collectively the results showed that increased expression of AKR1C3 had a significant influence on 
the flux through the 11OHA4 pathway, leading to the production of more potent androgens, but had 
little or no effect on the classical pathways. Increasing AKR1C3:17βHSD2 expression in both 
HEK293 and PC3 cells lead to increased levels of 11KA4 being converted to 11KT while the 
conversion of A4 to T remained low. A mathematical model was subsequently constructed and 
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confirmed the experimental findings. These results were further validated in three prostate cancer 
cell lines each expressing different AKR1C3:17βHSD2 ratios.  
Taken together, the results from this study show that 17βHSD2 likely plays an important role in 
regulating intratumoural androgen levels and that increased AKR1C3:17βHSD2 ratios favour the 
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Kastrasie weerstandige prostaat karsinoom (CRPC) is „n sieke wat aangedryf word deur die 
teenwoordigheid van kragtige androgene afkomstig van swakker adrenal voorlopers. Die 
alternatiewe 5α-dione padweg skakel die adrenale voorloper steroide DHEA(S) en 
androsteendioon (A4) om na die meer potente androgen dihidroksitestosteroon (DHT), terwyl die 
11β-hidroksiandrosteendione  (11OHA4) padweg die adrenal steroïed 11OHA4 omskakel na 
potente androgene soos 11-keto-testosteroon (11KT) and 11-keto-5α-dihidroksitestosteroon 
(11KDHT). 
Twee 17β-hidroksisteroïed dehidrogenase ensieme kataliseer belangrike reaksies in beide van 
bogenoemde padwee. Die ensiem 17βHSD2 kataliseer die oksidasie van potente androgene na 
swakker steroïede terwyl 17βHSD5, beter bekend as AKR1C3, die reduksie van potente 
androgene omskakel na swakker steroiede. Dus is die uitdrukkings vlakke van hierdie twee 
ensieme belangrik vir die regulering van potente androgene in die ligaam. Die doelwit van hierdie 
studie was dus om die aktiwiteit van die ensim 17βHSD2 te karakteriseer vir nuwe 11-
geoksideerde steroiede geproduseer deur die 11OHA4 padweg en die effek van verskillende 
verhoudings van AKR1C3:17βHSD2 op die vloed deur die alternatiewe 5α-dione en 11OHA4 
padweg te ondersoek.  
Die aktiwiteit van 17βHSD2  tot die 11-geoksideerde steroiede 11KT and 11KDHT was 
gekarakteriseer vir die eerste keer deur die uitdrukking van 17βHSD2 in HEK293 selle. Die 
resultate het getoon dat 17βHSD2 effektief 11KT sowel as 11KDHT omskakel na hul onderskeie 
produkte. Dis was interressant om waar te neem dat 17βHSD2 T meer effektief omskakel na A4 in 
vergelyking met die effektiwiteit van die omskakeling van 11KT tot 11KA4, alhoewel die verskil nie 
statisties relevant is nie. 
Die effek van „n toename in die verhouding tussen AKR1C3:17βHSD2, soos waargeneem in die 
geval van CRPC, was ondersoek. HEK293 selle wat geen van die twee bogenoemde ensieme 
uitdruk nie, was gemanipuleer om die ensiem van belang uit te druk waarna die selle gemeng is 
volgens die verhouding van AKR1C3:17βHSD2 verlang. PC3 cells wat reeds 17βHSD2 uitdruk 
was ook gemanipuleer om toenemende vlakke van AKR1C3 uit te druk.  
Saamgevat, bewys die resultate dat „n toename in die uitdrukking van AKR1C3 „n merkwaardige 
invloed op die vloed deur die 11OHA4 padweg gehad het wat tot gevolg lei tot die produksie van 
meer potente androgene, terwyl die teenoorgestelde is geldig vir die vloed deur die klassieke 
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padweg. Toenemende AKR1C3:17βHSD2 uitdrukking in beide die HEK293 en die PC3 selle het 
gelei tot „n toename in die produksie van 11KT vanaf 11KA4 terwyl die produksie van T vanaf A4 
konstant laag gebly het. „n Wiskundige model afgelei van die resultate wat bekom is, bevestig 
hierdie eksperimentele bevindinge. Verder was die resultate ook bevestig deur die drie PCa sel 
lyne wat verskillende verhoudings van AKR1C3:17βHSD2 uitdruk. 
Opgesom, bewys die resultate dat 17βHSD2 moontlik „n belangrike rol speel in die regulering van 
intratumorale androgeen vlakke en dat die toeneming in AKR1C3:17βHSD2 verhouding die vloed 
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  1  
 
 
 Chapter 1 
 
The role of 17βHSD enzymes in 
castration resistant prostate cancer 
 
1.1. The prostate 
 
The prostate is a tubuloalveolar exocrine gland which forms part of the male reproductive system. 
It is situated just under the bladder, in front of the rectum and surrounds part of the urethra (figure 
1.1) (1, 2). At birth the prostate has a volume of roughly 0.250 mL, which increases to 
approximately 10 mL at puberty and continues to increase throughout a male‟s lifetime. The 
average size of an adult male prostate is often described as being slightly larger than a walnut and 
having an average weight of 11 grams with a normal range of between 7-16 grams (3). Changes in 
prostate size, especially enlargements, are commonly associated with a number of different 
diseases and are thus an indicator that further diagnostic testing may be required (1).  
The prostate is not essential for survival, but plays an important role in male reproduction and 
fertility as it contributes to the composition of semen, providing sperm with zinc, citrate and fructose 
(1). The prostate also secretes proteins such as kallikrein-3 (KLK3), also known as prostate 
specific antigen (PSA), which is a protease responsible for the breakdown of large proteins in the 
seminal coagulum into smaller polypeptides thus helping to liquefy the semen (4). In a healthy 
male, PSA is contained within the prostate and very rarely leaks into the bloodstream (5). 
Disruption of the basement membrane occurs during the development of prostate cancer (PCa) 
and results in the leakage of PSA into circulation (5, 6). Serum PSA levels are therefore used as a 
biomarker for the detection of PCa but are not exclusive to PCa as PSA leakage also occurs due to 
other diseases of the prostate, such as benign prostatic hyperplasia (BPH), as well as during 
physical damage to the prostate (5).  
The prostate was originally divided into four lobes named the anterior lobe, the posterior lobe, the 
lateral lobe and the median or middle lobe (7). In 1968, John McNeal suggested revised 
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subdivisions of the prostate which he referred to as “zones” rather than lobes. He named these 
zones the peripheral zone, central zone, transition zone and the anterior fibro-muscular zone 
(stroma) (figure 1.1). It has since been observed that the peripheral zone is prone to the 
development of cancerous tumours (table 1.1), while the transition zone is more prone to the 





















The growth and maintenance of the healthy prostate is dependent on male sex hormones, which 
are known as androgens. Androgen levels in the foetus are high towards the end of gestation, but 
decrease after birth. Levels rise again during puberty as the testes begin to produce large amounts 
of the primary androgen, testosterone (T) (2, 10). Androgens are responsible for initiating prostate 
development, for the continues embryonic and neonatal prostatic growth and the initiation of the 
secretory activity of the prostate (2). The maintenance of the prostatic tissue and production of 
Figure 1.1: Schematic representation of the 
male reproductive system. The position of the 
prostate is pointed out by the square. Reproduced 
from:  https://en.wikipedia.org/wiki/Prostate#/media/
File:Prostatelead.jpg  
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secretory proteins, such as PSA, is controlled and maintained by androgens throughout a male‟s 
lifetime. The role of androgens in the development and maintenance of the prostate is especially 
clear when considering the termination of the secretory activity as well as apoptotic cell death and 
involution of the prostate gland which is observed following castration (2, 11, 12). The resumption 
of growth and function is observed following the administration of T (11). It should, however, be 
noted that while T is the primary androgen in male circulation within the prostate T is reduced to 
the more potent androgen, 5α-dihydrotestosterone (DHT), by the activity of steroid 5α-reductase 
(SRD5A). Inhibition of SRD5A reduces the development of the prostate, but does not completely 
inhibit it, thus demonstrating that there is not an absolute requirement for DHT in prostate 
maintenance, but that DHT is the more potent androgen (2, 13). 
 
Table 1.1: The four subdivisions of the prostate. The contribution to the mass/volume of the prostate and their 
susceptibility to prostate cancer (PCa) of each subdivision are also shown. Zones were first divided into lobes, 
which can now be associated with different zones as indicated below. 
 
1.2. Androgen signalling 
 
As mentioned above, androgens are essential for sexual development and reproductive function in 
males. The primary androgen T is produced by the Leydig cells of the testes under the control of 
the Hypothalamic-pituitary-gonadal (HPG) axis. Electrical pulses from neurons in the arcuate 
nucleus of the hypothalamus stimulate the release of gonadal releasing hormone (GnRH), which in 
turn stimulates the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from 
the pituitary. These hormones then stimulate the production of T and low levels of the estrogen, 
17β-estradiol (E2), by the Leydig cells. This process is tightly regulated by negative feedback, 
where both T and E2 inhibit the release of LH, FSH and GnRH (figure 1.2A) (15). As mentioned 
Zone 
Lobe corresponding 
to part of zone 


















Lateral lobe 5% - 
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above, T is reduced the more potent androgen, DHT, in peripheral target tissue such as the 
prostate which express SRD5A.  
The human adrenal cortex produces weakly androgenic androgen precursors such as 
dehydroepiandrostenedione sulphate (DHEA-S), dehydroepiandrostenedione (DHEA), 
androstenedione (A4) and 11β-hydroxyandrostenedione (11OHA4), which can all be converted to 
active androgens in peripheral tissue (16). Similar to GnRH, corticotropin-releasing hormone 
(CRH) regulates the release of adrenocorticotropin (ACTH) from the pituitary, which in turn, 
stimulate the production of steroids including cortisol and adrenal androgen precursors from the 
zona fasciculata and zona reticularis of the adrenal cortex, respectively (15). Cortisol in turn inhibits 
the release of CRH and ACTH through a negative feedback loop. This axis is referred to as the 
Hypothalamic-pituitary-adrenal (HPA) axis (figure 1.2B). In humans, the production of adrenal 
androgen precursors starts at ages between 6 and 8 years old and is not accompanied by 
increases in cortisol levels (12). These changes in androgen precursor levels as well as a sudden 
growth spurt and bone maturation forms part of a process known as adrenarche and are due to the 
development of the zona reticularis in the adrenal cortex. Adrenarche is independent of the HPG 






















   gland 
Adrenal 
HPG axis HPA axis 
(A)                                                       (B) 
Figure 1.2: Schematic representation of (A) the hypothalamus-pituitary-gonadal (HPG) axis and (B) the 
hypothalamus-pituitary-adrenal (HPA) axis. The HPG consists of a cascade of steps leading to the production of T and 
E2 by the Leydig cells of the testes. T and E2 inhibit the release of GnRH, LH and FSH through negative feedback loops. 
Similarly, the HPA consists of a cascade of steps leading to the release cortisol and the weak androgen precursor, DHEA-
S from the adrenal cortex. Cortisol inhibits the release of ACTH and CRH through a negative feedback loop. 
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Androgens act by binding to and activating the androgen receptor (AR). AR agonists include the 
potent androgens T and DHT. While both of these androgens have the ability to bind and activate 
the AR, the AR has a 10 times higher affinity for DHT (EC50 0.018 μM) than for T (EC50 0.195 nM) 
(17). Furthermore, DHT dissociates from the AR at a slower rate when compared to T (18).  
The AR is a member of a subfamily of nuclear receptors called NR3C4 (nuclear receptor subfamily 
3, group C, member 4) (19). This receptor consist of three function domains: the N-terminal 
transactivation domain; the DNA binding domain (DBD); and the C-terminal ligand binding domain 
(LBD) with a hinge region linking the DBD and LBD (18, 20). The functional domains share 
conserved areas with other steroid receptors such as the estrogen, progesterone (PROG), 
glucocorticoid, and mineralocorticoid receptors (21, 22). Nuclear receptors can regulate gene 
expression by activating or suppressing the transcription of specific genes. The AR can activate 
transcription by binding to cis-acting DNA elements or repress gene transcription by binding to a 
cis-negative DNA motifs. The AR can also interact with other trans-acting factors such as the 
protein complex nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) through 
protein–protein interaction leading to transcriptional interference also known as transrepression 
(23–26). 
During transactivation an agonist binds to the AR and the receptor undergoes a conformational 
change and dissociates from the heat shock proteins (HSP) with which it is complexed. The 
activated receptor subsequently forms a homodimer with another activated receptor. The 
dimerized complex translocates into the nucleus where it binds to a 15 bp DNA element, called the 
AR-response element (ARE). This transactivates the transcription of androgen-regulated genes, 
such as PSA, which are essential for the development of male sexual characteristics and male 
reproductive function (18, 27, 28).  
Negative gene regulation can be divided into two types, namely repression and transrepression. 
During repression, the receptor binds to the DNA response element but instead of eliciting a 
transcriptional response it inhibits transcription. This includes ligand independent repression in 
which unliganded receptor homodimers binding to the DNA response element and inhibit 
transcription (29). During transrepression the ligand-activated AR does not bind to DNA, but 
instead has a protein-protein interaction with promoter-bound transcription factors. This interferes 
with the initiation of transcription and the gene is thus repressed (29). An example of this is the 
inhibition of c-Jun and c-Fos activity, which together form part of the AP-1 early response 
transcription factor, by direct protein-protein interaction with the AR. This mechanism interferes 
with the subsequent binding of co-activators (30, 31). Another example is the protein-protein 
interaction which is seen between the AR and the transcription factor NF-κB. The AR results in the 
transrepression of genes regulated by NF-κB, which include immunoregulatory proteins, cytokines, 
rel/lκB protein, cyclins, growth factors and regulators of apoptosis (30). 
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1.3. Prostate cancer 
 
Global statistics suggest that one in every seven men will be diagnosed with PCa during their 
lifetime (32). A cancer profile research report by the world health organisation (WHO) estimated 
that 9957 men were diagnosed with PCa in South Africa in 2014, almost twice as many as men 
diagnosed with lung cancer for that same year (32). A total of 20 700 male deaths were attributed 
to cancer in 2014 in South Africa, of which 16% were due to PCa (5). 
The development of PCa can be attributed to several different factors. Alterations in the 
phosphatidylinositol 3-kinase (PI3K) signalling pathway, which is responsible for promoting the 
growth of cells and preventing apoptosis, have been found in 40% of primary PCa and 70% of 
metastatic PCa cases (27, 33–35). Increased expression of oncogenes and the down regulation of 
tumour suppressor genes have also been shown to play an important role in PCa development. 
For example, the transcription factor, c-myc, which plays a role in cell cycle progression and 
apoptosis is commonly overexpressed, while the RNA binding protein involved in nuclear 
processes, p53, and the tumour suppressor protein, Rb, are down regulated or inactivated, though 
the incidence of these changes were found to be more common in metastatic tumours than in 
primary tumours (35). Concomitant alterations and mutations in the AR have also been observed in 
PCa cells, and will be discussed in more detail in section 1.4.1. (27). Recurring chromosomal 
translocations resulting in the formation of fusion proteins that contribute to PCa development are 
also common (27). The 5' untranslated region of the transmembrane protease serine 2 
(TMPRSS2) was found to fuse to the oncogene ERG in cancers which over expresses erythroblast 
transformation-specific (ETS) family members (36–39). Fusions include TMPRSS2-ERG, 
TMPRSS2-ETV1 (37, 40) and TMPRSS2-ETV4 (38, 40). TMPRSS2 is highly specific to prostate 
tissue and is localized to the prostate luminal epithelial cells (37, 40). Cerveira et al. and Tomlins et 
al. have shown that androgen stimulation can cause the over expression of ERG in a TMPRSS2-
ERG positive cell line and this deregulation of ERG through the androgen dependent activation of 
TMPRSS2 has been suggested to alter cell proliferation and apoptosis (37, 40, 41).  
 
1.4. Castration resistant prostate cancer (CRPC) 
 
PCa, like the healthy prostate, is dependent on the activation of AR signalling. In 1966, before the 
discovery of the AR, Charles Huggins was awarded the Nobel Prize for showing that 
supplementation with T increased the growth of prostate tumours in rats, while castration led to a 
delay in the growth of the tumour (18, 44). While PCa can initially be treated with radiation therapy 
and chemotherapy, metastatic cancers are treated using androgen deprivation therapy (ADT) (27). 
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The aim of ADT is to prevent the production of T by the testes and is accomplished by chemical or 
surgical castration. Chemical castration is achieved by the administration of luteinizing hormone-
releasing hormone (LHRH) agonists such as leuprolide and is often accompanied by treatment 
with AR antagonists such as bicalutamide or flutamide (42). ADT treatment results in a decrease in 
the activation of AR and ultimately leads to tumour regression. While ADT is initially effective, in 
most cases the cancer re-emerges after 2-3 years in an aggressive and fatal form known as 
castration resistant prostate cancer (CRPC) (42). Men aged 65 and older are especially prone to 
developing CRPC (43).  
Robinson et al. recently conducted a comprehensive study investigating genomic alterations in 
patients affected by CRPC (figure 1.3). The aim of the study was to identify discrete molecular 
subtypes of CRPC, considering short insertion/deletions, copy number alterations and fusion 
transcripts (figure 1.3) (44). 
Alterations in the PI3K pathway were found in 49% of individuals affected by CRPC. This pathway 
consists of enzymes involved in a variety of cellular functions such as cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking. Alterations in this pathway include 
biallelic (pertaining to both alleles, both alternative forms of a gene) loss of phosphatase and tensin 
homolog (PTEN), hotspot mutations, amplifications and triggering fusions in PIK3CA, and p.E17K 
activating mutations in the Akt1 gene which encodes for the RAC-alpha serine/threonine-protein 
kinase and which plays a role in metabolism, growth, proliferation, survival, transcription and 
protein synthesis through serine and/or threonine phosphorylation of a range of downstream 
targets (44). 
Mutations in the Wnt signalling pathway were found in 18% of cases and including hotspot 
activated mutations previously found in Catenin beta-1 encoding gene  (CTNNB1) (45) and 
recurrent alterations in Adenomatous polyposis coli  (APC) (44). This pathway is involved in 
cellular processes including cell fate determination, motility, polarity, primary axis formation and 
organogenesis and has also been implicated in stem cell renewal (46). In the case of CRPC, 
studies recently identified alterations in Ring Finger Protein 43 (RNF43) and Zinc And Ring Finger 
3 (ZNRF3) which were also previously found in colorectal, endometrial and adrenocortical cancers 
(44, 47, 48). These were conjointly exclusive with APC alterations. Studies also found R-Spondin 2 
(RSPO2) fusions in association with RSPO2 overexpression also previously observed in colorectal 
cancers (44, 49).  
A loss in tumour suppressor gene encoding for the production of retinoblastoma protein (RB1) was 
observed in 21% of CRPC cases (44). Further expanding the scope of CRPC cell cycle gene 
alterations they found focal amplification involving the cyclin D1 encoding gene (CCND1) in 9% of 
the cases and less common events involving CDKNZA/B. This results in cell cycle instability and 
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can lead to enhanced response to CDK4 inhibitors in other tumour types and is predicted to have 
similar activity in PCa (44, 50). 
Twenty-three percent of CRPC cases involve alterations in DNA repair pathways with 12.7% of 
those including the loss in the tumour suppressor gene, BRCA2 which encodes for breast cancer 
type 2 susceptibility proteins. Up to 90% of these losses were found to be biallelic and were mostly 
due to somatic point deletions (44). Further studies revealed that 22.7% cases of CRPC contained 




















Alterations in the AR signalling pathway, mostly amplifications and mutations, were found in 71.3% 
cases of CRPC (44). These included changes to the AR itself, as well as changes to FOXA1, 
NCOR1/2, SPOP (52), and ZBTB16 (44). Mutations in the AR were found to occur at residues 
which were previously found to confer agonism to AR antagonists including flutamide (T878A) and 
Figure 1.3: Common pathways altered in CRPC. Schematic showing the five most common 
pathways which are altered in metastatic castration-resistant prostate cancer. Reproduced with 
permission from: Robinson et al. (2016) Integrative Clinical Genomics of Advanced Prostate 
Cancer. Cell. 161, 1215–1228. 
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bicalutamide (W742C) (44). FOXA1, NCOR1 and NCOR2 are responsible for the regulation of the 
AR, and were found to be altered in both primary cancers and CRPC while ZBTB16 plays and role 
in cell cycle progression, and interacts with a histone deacetylase (44, 53, 54). 
 
1.4.1. Androgen receptor mutations 
Mechanisms proposed as an explanation for the development of CRPC were at first directed 
towards finding alterations in AR structure, function and ligand binding. This included the over 
expression of the AR, AR gene mutations, enhanced AR signal transduction through downstream 
regulatory molecules, co-factor recruitment alterations (increase expression of transcriptional co-
activator proteins), cross-talk leading to the activation of the receptor independent of ligand binding 
and AR splice alternatives (55–58)  (figure 1.4). AR mutations where found to occur in up to 40% 
(57, 59, 60) of primary tumours while up to 50% (57, 61) of recurrent tumours presented AR 
mutations.  
Alterations in the steroid binding specificity of the AR increases the range of ligands which are able 
to bind and possibly activate the receptor (57, 62–64). Studies have also observed a correlation 
between the depletion of androgens and mutations in the functional domain of the AR which is 


















Mutation of AR 
AR amplification 
Alternative 
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Figure 1.4: Alterations and mutations of the androgen receptor which could contribute to the development of 
CRPC. Adapted from: Anantharaman, A; Friedlander, T W. (2015) Targeting the androgen receptor in metastatic 
castrate-resistant prostate cancer: A review. Urologic Oncology: Seminars and Original Investigations. 34, 356–367. 
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Gregory et al. showed both an increase in the expression and stability of the AR as well as an 
increase in the sensitivity of this receptor for its ligand in recurrent tumours (66, 67). Chen et al. 
suggested that an increase in AR expression is essential for the progression from androgen-
dependent to castration-resistant cancer. They observed an increase in AR expression sufficient to 
be activated in the presence of a 80% reduction in normal intra-prostatic androgen concentrations 
(55). It is commonly believed that an increase in AR expression and structural stability combined 
with an increased sensitivity for lower levels of androgens such as DHT will lead to continued 
proliferation of cells even after ADT. Enhanced sensitivity of AR signalling has also been shown to 
be due to alterations in other signal transduction pathways including the RAS/Raf/MAP, protein 
kinase A (PKA) and PI3K pathways (68). 
In addition, a number of pathways can crosstalk with AR signalling. During non-genomic AR 
signalling cytoplasmic ligand bound AR can facilitate the activation of kinase-signalling cascades 
including Ras-Raf-1, PI3K/Akt and PKA, leading to the activation of mitogen-activated protein 
kinase (MAPK)/extracellular signal-regulated kinase (ERK) which ultimately leads to cell 
proliferation (69). Other signalling pathways can also lead to the activation of the AR without the 
need for androgens. For example, the cyclic adenosine monophosphate activated protein kinase A 
(cAMP/PKA) pathway can activate the AR, leading to increased PSA expression, in an androgen 
independent manner (70) thus contributing to PCa progression (71). It should, however, be noted 
that an increase in PSA gene expression via PKA still requires a functional AR (70, 72). ERK may 
also phosphorylate the AR as well as its co-activators, leading to enhanced genomic AR activity in 
the presence of a ligand. This could also occur in an ERK-independent manner by the activation of 
the rapamycin (mTOR) pathway or intracellular Ca+2 level modulations by plasma membrane G 
protein-coupled receptors (GPCRs) (69). While the mechanisms described above have been 
shown to play important roles in the development of CRPC, in most cases the activation of the AR 
is still dependent on the binding of a ligand (66). An AR splice variant, AR-V7, which lacks a 
functional LBD has however been shown to activate AR reporter genes in the absence of ligand 
and is therefore believed to play a role in some CRPC cases (73).  
 
1.4.2. CRPC is an androgen dependant disease 
CRPC was formerly known as androgen independent hormone refractory PCa, as it was believed 
to be independent of androgens. Studies have since shown that in most cases CRPC remains 
androgen-dependent (57, 74). Mohler et al. (57) therefore proposed that CRPC should be referred 
to as a recurrent disease and not an androgen independent disease. Imaging and cytology 
experiments have revealed that while castration inhibits the activation of AR signalling this activity 
is reactivated during the development of CRPC and is accompanied by a concomitant increase in 
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PSA levels (19, 66, 75, 76). Mostaghel et al. (77–79) have confirmed that the progression of CRPC 
correlates with an increase in PSA levels and that PSA remains in the top 1% of all genes 
expressed in CRPC tumours (77–79). The dependence of CRPC on the presence of androgens 
have since been confirmed by clinical studies which have shown that the anti-androgens, 
Abiraterone (CYP17A1 inhibitor) and Enzalutamide (AR antagonist), significantly improve patient 
outcomes (80).  
Abiraterone inhibits the key steroidogenic enzyme Cytochrome P450 17α-hydroxylase/17,20-lyase 
(CYP17A1), which is essential for the production of all androgens and androgen precursors. Attard 
et al., (74) treated 21 chemotherapy-naïve patients with 250-2000 mg Abiraterone acetate per day. 
They found that within 8 days of treatment the T levels of the participating patients dropped from a 
median of 7ng/dL to an undetectable level and remained at these levels for the duration of the 
treatment period. DHEA levels were found to decrease by 70.4% within 28 days after treatment. 
Decreases in DHEA and E2 levels were also observed. Conversely the inhibition of CYP17A1 
resulted in significant increase in up-stream steroid metabolites. For example, a 40-fold increase in 
corticosterone and a 10-fold increase in 11-deoxycorticosterone (DOC) levels were observed. 
Additionally, a 6-fold increase in ACTH was observed. Notably, Attard et al. (74) found that 66% of 
the patients receiving treatment showed a 30% or more decrease in PSA levels three months after 
treatment was initiated. 
 
Table 1.2: Androgen levels in different prostate tissues. Mean tissue 
androgen levels in castration resistant metastases from anorchid patients 
versus primary prostate tissues from eugonadal men. Adapted from: R. B. 
Montgomery et al. (2008) Maintenance of Intratumoural Androgens in 
Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumour 


















Benign prostate 0.04 (0.00–0.24) 
1.92 (1.63–2.21) 
 
Cancer prostate 0.23 (0.03–0.44) 
2.75 (2.45–3.04) 
 
Control tissueᵻ 0.10 (0.00–0.26) 
0.05 (0.00–0.30) 
 
Metastatic tissue 0.74 (0.59–0.89) 0.25 (0.00–0.50) 
Abbreviation: 95% CI, 95% confidence interval. 
*P < 0.0001 for comparison among benign prostrate versus cancer prostrate, control 
tissue versus metastatic tissue, and cancer prostrate versus metastatic tissue for both 
testosterone and DHT (except P= 0.01 for difference in testosterone between benign 
prostate and cancer prostrate).  
ᵻ
Nontumour tissues were obtained concurrently with tumour metastases from men with 
CRPC. 
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A study by Ryan et al. (81) investigated the effect of 1000 mg abiraterone on the life expectancy of 
1088 asymptomatic chemotherapy-naïve PCa patients. The group was divided into two sections, 
one receiving abiraterone treatment and the other receiving a placebo treatment. Results showed 
that the median overall survival was significantly longer in the abiraterone group (34.7 months) 
compared to the placebo group (30.3 months) (81).  
In contrast to Abiraterone, Enzalutamide is a nonsteriodal antiandrogen which acts as an AR 
antagonist by binding to the LBD of the AR thereby preventing nuclear translocation of the 
receptor, DNA binding and the recruitment of co-activators (82). Cabot et al. (82) showed that 
metastatic CRPC patients receiving Enzalutamide had an extended life expectancy compared to 
the placebo group not receiving the treatment (18.4 months vs 13.6 months). Enzalutamide was 
shown to lower the risk of fatality by 37% and delayed the growth of the tumour despite the 
presence of low concentrations of androgens (82). Enzalutamide was also shown to result in the 
reduction of tumour sizes during xenograph studies (82). Taken together, these results shifted the 
spotlight to the levels of androgens and their sources following ADT. 
A study by Sharifi and Auchus (15) showed that intratumoural levels of DHT were approximately 1 
nM (0.5 ng/g - 1.0 ng/g) in patients after castration and that these levels were sufficient for the 
activation of the AR. In fact these levels of DHT have been suggested to be 50-fold higher than the 
concentration required for half maximal activation of AR (15, 17). Montgomery et al. (66) suggested 
that there are two ways in which these intratumoural androgen concentrations can be supported 
during CRPC. First is the uptake and conversion of androgen precursors produced by the adrenal 
and second the de novo synthesis of androgens in peripheral tissue. Studies have since shown 
that a major contributing factor to intratumoural androgen levels is the intratumoural conversion of 




All steroid hormones are derived from cholesterol and thus share a common 
cyclopentanophenanthrene-4-ring structure. The first steroid hormones to be discovered were 
divided into the androgens and estrogens based on their physiological effects. Androgens are 
broadly considered to be male sex hormones while estrogens are considered female sex steroids. 
Later the progestogens, mineralocorticoids and glucocorticoids were also placed into their 
according groups based on their function (9).  
Progestogens, such as PROG, are also sex steroids and play an important role in normal 
reproductive functions, which include ovulation, uterine and mammary gland development as well 
as neurobehavioral expression associated with sexual responsiveness (84–86). Glucocorticoids, 
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such as cortisol, are responsible for the regulation of carbohydrate, protein and fat metabolism, as 
well as the  modulation of immune function (18, 87, 88). The mineralocorticoid aldosterone 
regulates water and salt balance by regulating the reabsorption of sodium from the distal 
convoluted and cortical collecting tube of the kidney (18, 89–93). 
The primary sites of de novo steroid biosynthesis (steroidogenesis) in men are the testis (Leydig 
cells) and the adrenal cortex. Two major groups of enzymes are required for steroid biosynthesis – 
the cytochrome P450s (CYP) and the hydroxysteroid dehydrogenases (HSD). 
 
1.5.1. Cytochrome P450 enzymes 
The majority of mammalian CYP enzymes consist of approximately 500 amino acid residues. All 
CYPs contain a single heme group which is essential for catalytic function (94, 95). These 
enzymes are oxidative in nature and catalyse physiologically and mechanically non-reversible 
reactions. In their reduced state and with carbon monoxide bound as a ligand the CYP enzymes 
demonstrate a characteristic absorption maximum of 450 nm. CYP enzymes can be divided into 
two groups, namely type 1 CYPs, which are found in the mitochondria and accept electrons from 
NADPH, via ferredoxin reductase and ferredoxin, and type 2 enzymes which are located in the 
endoplasmic reticulum and accept electrons from NADPH via P450 oxidoreductase (POR) (95, 
96). CYP enzymes are responsible for the metabolism of a variety of xenobiotics in the liver and 
the biosynthesis of steroid hormones in the adrenal and gonads. The CYP catalytic cycle is 
complex and includes the activation and cleavage of molecular oxygen, with one atom of oxygen 
being included in the substrate and the other released as water (95).  
 
1.5.2. Hydroxysteroid dehydrogenase (HSD) 
Hydroxysteroid dehydrogenases (HSDs) are a group of enzymes which are usually 35-45 kDa in 
size (95). These enzymes make use of either NADH/NAD+ or NADPH/NADP+ as co-factors to 
catalyse redox reactions such as the conversion of a secondary alcohol to a ketone (94, 97). HSD 
catalysed reactions are reversible under controlled conditions in vitro, but one reaction is usually 
dominant in vivo.  
HSD enzymes are classified according to their structure or function. Structurally HSD enzymes are 
classified as either short-chain dehydrogenases/reductases (SDRs) or Aldo-keto reductases (AKR) 
(95, 97, 98). The tertiary structure of SDRs consist of a Rossman fold, or β-α-β secondary 
structure, which is a characteristic of oxidation/reduction enzymes that utilize nicotinamide as 
cofactor  (95, 97, 98). In contrast, the tertiary structure of AKR enzymes consist of either β-barrels 
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or triosephosphate isomerase (TIM-barrels) motifs (95, 97, 98). Both SDRs and AKRs contain 
tyrosine and lysine residues in their active site and these residues play an important role in 
substrate binding and specificity (95, 97, 98).  
Functionally the steroid metabolising HSD enzymes, are divided into one of two groups – the 
dehydrogenases and reductases (95, 97, 98). Enzymes classified as dehydrogenases use NAD+ 
as cofactor to oxidise their substrate from a hydroxysteroid to ketosteroid (95, 97, 98). Conversely, 
reductases use NADPH to reduce ketosteroids to hydroxysteroids (95, 97, 98). Thermodynamic 
analysis of HSD enzymes indicated that these enzymes prefer the reduction of ketosteroids. 
Concomitantly, the oxidative enzymes need to overcome an uphill thermodynamic hurdle (97). This 
is accomplished by the availability of cofactors. For example, in vivo the catalytic activity of 
11βHSD1 is dependent on the presence of the cofactor NADPH in order to catalyse the reduction 
of cortisone to cortisol (99). A high NADPH/NADP+ ratio is maintained by the co-expression of 
hexose-6-phosphate deyhydrogenase (H6PDH) which catalyses the conversion of glucose-6-
phosphate to 6-phosphogluconate and is coupled to the reduction of NADP+ to NADPH. In H6PDH 
knockout mice, the drop in NADPH concentration results in 11βHSD1 acting as a dehydrogenase 
instead of a reductase (99). H6PDH thus regulates the directionality of 11βHSD1 activity in vivo 
(99–101).   
 
1.5.3. Steroidogenesis in the testis 
Steroidogenesis starts with the transfer of cholesterol from the outer to the inner membrane of the 
mitochondria by the steroidogenic acute regulatory protein (StAR) as can be seen in figure 1.5. 
Thereafter cholesterol undergoes side-chain cleavage to produce pregnenolone (PREG), a 
reaction which is catalysed by cytochrome P450 side-chain cleavage (CYP11A1). PREG is 
subsequently converted to 17α-hydroxypregnenolone (17OHPREG) by the 17α-hydroxylase 
activity of CYP17A1 (figure 1.5). The 17,20-lyase activity of CYP17A1, which is augmented by 
cytochrome b5, then results in the cleavage of the 17-20 carbon bond leading to the production of 
DHEA. 3βHSD2 subsequently converts DHEA to A4, which is then converted to T by 17βHSD3 
(94) (figure 1.5). The production of T by the Leydig cells is regulated by the HPG-axis as discussed 
in section 1.2. This axis regulates the expression of CYP11A1 and CYP17A1 as well as the 
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1.5.4. Steroidogenesis in the adrenal 
The adrenal cortex is divided into three zones, which differ in the enzymes they express and as a 
result their steroid output (95, 102). All three zones express CYP11A1 and StAR. The zona 
glomerulosa also expresses 3βHSD2, CYP21A2 and cytochrome P450 aldosterone synthase 
(CYP11B2) thus leading to the production of the mineralocorticoid aldosterone. The zona 
fasciculata expresses CYP17A1, 3βHSD2, CYP21A2, and CYP11B1 resulting in the production of 
the glucocorticoid cortisol (figure 1.6) (95, 103). The zona reticularis expresses high levels of 
CYP17A1 and cytochrome b5 resulting in the synthesis of high levels of DHEA (figure 1.6). The 
majority of DHEA is sulphated by the activity of SULTA2 leading to the production of DHEA-S (95, 
102, 104, 105). DHEA is also converted to A4 by the activity of 3βHSD2 (figure 1.7). Besides the 
production of A4 and DHEA, the adrenal also produces the 11-oxygenated C19 steroid precursor 
11OHA4. A4 is converted to 11OHA4 in the adrenal by the P450 enzyme, CYP11B1. Interestingly, 
11OHA4 has been shown to be more abundant in adrenal vein samples when compared to A4 with 
low levels of 11KA4, 11OHT and 11KT also being produced (figure 1.6) (106–108).  
 
















Figure 1.5: Schematic of steroidogenesis in the Leydig cells of the testes. 
CYP17 
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1.5.5. Steroid metabolism in CRPC 
1.5.5.1. The Alternative pathway (5α-dione pathway) 
Circulating levels of T are reduced significantly following ADT (<50 ng/dL) (109, 110). Studies have 













































Figure 1.6: Schematic of steroidogenesis in the adrenal gland. 
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the adrenal steroid DHEA is converted to A4 by the activity of 3βHSD. It was initially assumed that 
the resulting A4, together with A4 from circulation, is subsequently converted to T by the reductive 
17βHSD enzymes followed by the reduction of T to DHT by SRD5A (classical pathway). A study 
done by Chang et al. however showed that the development and progression of CRPC is driven by 
an alternative pathway to DHT which bypasses T production. In this pathway A4 is preferentially 
reduced by 5α-reductase type 1 (SRD5A1) yielding 5α-dione, which is subsequently converted 






Chang et al. used six human PCa cell lines, to investigate the metabolism of A4. The cells where 
supplemented with [3H]-A4 and the levels of the resulting metabolites, including 5α-dione and T, 
were separated by high pressure liquid chromatography (HPLC) and measured using a radioactive 
detector. The flux from A4 to 5α-dione was more rapid than the conversion of A4 to T for all six cell 
lines. These findings were subsequently confirmed using LAPC4 and LNCaP xenograft models in 
Figure 1.7: The metabolism of A4 to DHT in 
CRPC. The preferred alternative pathway is shown 
in red.  
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surgically castrated mice supplemented with T or A4 as well as by quantifying steroid levels in 
tumour biopsies from patients with CRPC (111).  
The flux through the alternative 5α-dione pathway has been shown to be due to the preference of 
SRD5A1 for A4 as a substrate. While both T and A4 have a ∆4, 3-keto structure and are both thus 
susceptible to 5α-reduction by SRD5A1, A4 is more efficiently reduced (111). During the 
development of CRPC the expression of SRD5A2 is decreased by approximately 50%, while the 
expression of SRD5A1 is significantly upregulated (112). The increased levels of SRD5A1 
therefore favour the reduction of A4 to 5α-dione pushing the flux towards the synthesis of DHT, 
while bypassing T. 
1.5.5.2. The 11β-hydroxyandrostenedione pathway 
The human adrenal gland produces large quantities of the C19 steroid 11OHA4 in addition to the 
androgen precursors DHEA-S, DHEA and A4 (106–108). 11OHA4 is in fact approximately two 
times more abundant than A4 in adrenal vein samples in both in unstimulated and ACTH 
stimulated conditions (106). For many years the 11β-hydroxylation of A4 to 11OHA4 by CYP11B1 
was believed to be a manner of inactivating A4, preventing it from being further metabolised to 
androgens such as T and DHT (108, 113).  
Our group has, however, shown that 11OHA4 is not a dead-end product of adrenal 
steroidogenesis, but that it is a precursor to active androgens including 11-ketotestosterone 
(11KT), and 11-ketodihydrotestosterone (11KDHT) (108, 113). In addition to 11OHA4 the adrenal 
also produces low levels of 11KA4, 11OHT and 11KT (113) (figure 1.8). 
Storbeck et al. (108) showed that 11OHA4 is metabolised by the activity of 11βHSD, SRD5A and 
17βHSD which are all expressed in the prostate. In the preferred route 11OHA4 is converted to 
11KA4 by 11βHSD2. AKR1C3 subsequently reduces 11KA4 to produce 11KT, which can further 
be converted to 11KDHT by SRD5A1 (107, 108) Interestingly, Storbeck et al. (106, unpublished 
data) showed that 11OHA4 cannot be converted to 11OHT by either AKR1C3 or 17βHSD3. 
11OHT is however produced by the direct 11β-hydroxylation of T in both the adrenal  (106, 107) 
and possibly the testes (114). 11OHT can be converted to 11KT by 11βHSD2 or to 11OHA4 by 
17βHSD2 (16). 
Storbeck et al. (108) subsequently tested the relative androgenic activity of the metabolites 
identified in the 11OHA4 pathway using a promoter reporter based transactivation assay. The 
androgenic activity of 1 nM of the metabolites was calculated relative to that of DHT, which was set 
at 100% (figure 1.9). While 11OHDHT was found to be only a partial agonist with 47% activity, 
11KDHT demonstrated full agonist activity (96%). (108). Interestingly, T and 11KT also exhibited  
similar agonistic activity of 61% and 62% respectively (108). Only 30% agonist activity was, 
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however, observed for 11OHT, while no activity was observed for 11OHA4, 11OH-5α-dione or 






A study by Pretorius et al. (115) subsequently compared the androgenic activity of 11KT and 
11KDHT to that of T and DHT, respectively. First using whole cell binding assays they found that 
the human AR has similar binding affinities for 11KT, 11KDHT, T and DHT (figure 1.10). Next using 
promoter reporter assays with a selective androgen response element (ARE) they found that 11KT, 
11KDHT, T and DHT are all full AR agonists with similar efficiencies and that 11KDHT and DHT 
are equipotent. Similarly 11KT and T were found to be equipotent (115). 
Figure 1.8: The 11OHA4 pathway.  The weak precursor 11OHA4 is converted to more potent 
androgens 11KT and 11KDHT by the enzymes 17βHSD, SRD5A and 11βHSD. The preferred pathway is 
shown in red. 
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Pretorius et al. went on to show that the rate of metabolism was significantly higher for T and DHT 
in both VCaP and LNCaP cell lines when compared to 11KT and 11KDHT (figure 1.12). Thus 11KT 
and 11KDHT have the potential to remain active longer as they are metabolised at a lower rate 
(115). 
Pretorius et al. also investigated the effect of DHT, 11KDHT, T and 11KT on the mRNA expression 
levels of three AR regulated genes in LNCaP (mutated AR) and VCaP (wild type AR) PCa cell lines 
as well as the alterations in protein expression in VCaP cells. They also went on to investigate the 
effect of these 11-oxygenated steroids on the proliferation of the above mentioned PCa cell lines.  
Their results showed that 11KDHT and 11KT were able to upregulate all three AR regulated genes 
investigated (KLK3, TMPRSS2 and FKBP5) in LNCaP and VCaP cells and that both 11KDHT and 
11KT induced cell growth in both androgen dependent cell lines (figure 1.11). Interestingly, they 
observed that 11KT and 11KDHT resulted in higher fold induction of KLK3, FKBPS and TMPRSS2 
in LNCaP cells when compared to T and DHT (115). Proteomic analysis of VCaPs treated with 
DHT, 11KDHT, T and 11KT confirmed that 11KT and 11KDHT could regulate the expression of 
Figure 1.9: Transactivation of the human androgen receptor (AR) by 1 nM C19 
steroids. Reproduced with permission from: Storbeck, K.-H., Bloem, L. M., Africander, D., 
Schloms, L., Swart, P., and Swart, A. C. (2013) 11β-Hydroxydihydrotestosterone and 11-
ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in 
castration resistant prostate cancer. Mol. Cell. Endocrinol. 377, 135–46. 
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known androgen regulated proteins. Taken together their results confirmed that these 11-
oxygenated steroids were bona fide androgens capable of inducing the expression of endogenous 
AR regulated genes. 
 
Figure 1.10: Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the 
synthetic AR agonist mibolerone. Reproduced with permission from: Pretorius, E., Africander, D. J., Vlok, M., Perkins, 
M. S., Quanson, J., Storbeck, K.-H. (2016) 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant 
Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. PLoS One. 
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Figure 1.12: Metabolism  of DHT, 11KDHT, T and 11KT by LNCaP and VCaP cells. Reproduced with permission 
from: Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., Storbeck, K.-H. (2016) 11-Ketotestosterone 
and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be 
Ignored. PLoS One. 
 
Figure 1.11 Induction of cell proliferation in LNCaP and VCaP cells by DHT, 11KDHT, T and 11KT. Reproduced 
with permission from: Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., Storbeck, K.-H. (2016) 11-
Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which 
Can No Longer Be Ignored. PLoS One. 
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1.6. The role of 17βHSD2 and AKR1C3 in CRPC 
 
From section 1.5.2. and section 1.5.4. it is clear that both AKR1C3 and 17βHSD2 play vital roles in 
both the 5α-dione and 11OHA4 pathways. In both pathways AKR1C3 is essential for the 
conversion of androgen precursors to active androgens, while 17βHSD2 catalyses the reverse 
reaction, potentially inactivating active androgens. 
 
1.6.1. AKR1C3 
AKR1C3 (17βHSD5) was originally considered to be a 3α-Hydroxysteroid dehydrogenase (3αHSD) 
before being re-classified as an AKR (95, 116, 117). It utilizes NADH and/or NADPH as cofactor 
and like 17βHSD3, it catalyses the 17-keto reduction of androgen precursors such as A4 to more 
potent androgens such as T. AKR1C3 also possesses 3α-HSD activity and catalyses the 
conversion of DHT to the less potent 5α-adiol. Reactions catalysed by AKR1C3 involve the binding 
of the substrate and cofactor and follow a Bi-Bi sequential reaction mechanism with the cofactor 
binding before the substrate (118).  
Members of the AKR superfamily show high amino acid sequence identity and share a common 
(α/β)8-barrel protein fold. Differences are however observed within the 8 α-helices and 8 β-strands. 
Three large discorded loops (A, B and C) are visible at the back of the protein structure and 
undergo a conformational change during the binding of the substrate and cofactor. 
The active site of AKR enzymes consists of a large, deep elliptical pocket at the COOH-terminal 
end of the protein. The active site is highly hydrophobic and favours aromatic and apolar 
substrates above highly polar molecules. A conserved catalytic tetrad, Y55, H117, D50 and K84 is 
present at the base of the β-barrel where Y55 acts as a general acid/base catalyst (21, 22). 
Although the binding site for the cofactor is highly conserved the flexible loops can accommodate 
assorted structural units. Of the 84 AKR structures listed in the protein-data bank (PDB) a number 
of structures exists for binary and ternary complexes that form in the reaction mechanism.  
While 17βHSD3 is almost exclusively expressed in the testes, AKR1C3 is responsible for the 
production of extra-testicular conversion of A4 to T in non-steroidogenic peripheral tissues such as 
the prostate (95, 119). Thus it is no surprise that this enzyme is dominantly expressed in human 
prostate and mammary gland (120). A previous study by our group found that the conversion of 
11KA4 to 11KT by AKR1C3 may be preferred over the conversion of A4 to T (figure 1.13). An 
investigation into the catalytic activity and substrate preference of AKR1C3 is currently underway in 
our group.  
Stellenbosch University https://scholar.sun.ac.za 
 
 
















The upregulation of AKR1C3 expression in the prostate seems to play an important role in the 
development of CRPC (table 1.3). Stanbrough et al. (121) compared gene expression profiles in 33 
patients exhibiting CPRC to that of 22 patients with primary PCa in an attempt to identify altered 
gene expression profiles which may contribute to the development of CRPC. Results showed an 
increase in the expression of genes encoding for AKR1C3, SRD5A1 as well as 3βHSD2. 
Immunohistochemistry confirmed that AKR1C3 expression was increased up to 5.3 fold in CRPC 
samples (121). Similarly, Jernberg et al. (122) investigated altered enzyme expression in CRPC 
bone metastases samples. Expression levels were analysed using qPCR, immunohistochemistry 
and immunoblotting. Results indicated significantly higher levels of AKR1C3 mRNA compared to 
non-malignant and/or malignant prostate tissue.  
Immunostaining total score was highly correlated to the AKR1C3 mRNA levels in the 
corresponding metastases. Pfeiffer et al. (123) investigated gene expression profiles in CRPC 
using microarrays and qPCR and observed an increase in the expression of AKR1C3 in CRPC. 
Byrns et al. (124) investigated the effect of overexpressing AKR1C3 in LNCaP cells which have 
low levels of endogenous AKR1C3. In the absence of AKR1C3, the LNCaP cells predominantly 
produced 5α-dione when A4 was given as substrate. These cells ceased to proliferate when 
treated with the SRD5A inhibitor, finasteride. Conversely, the overexpression of AKR1C3 







A4     T











Figure 1.13: The metabolism of A4 and 11KA4 by AKR1C3. 
A time course for the conversion of 1 μM 11KA4 and A4 to 
11KT and T, respectively by AKR1C3 suggests that 11KA4 is 
the preferred substrate. Unpublished data from the Storbeck 
laboratory. 
Stellenbosch University https://scholar.sun.ac.za 
 
 
   25 
 
increased the conversion of A4 to T and resulted in the development of finasteride resistance 
(124).  
 
Table 1.3: Altered enzyme expression levels observed in prostate cancer (PCa) compared to castration resistant 
prostate cancer (CRPC) as well as the direction of the reaction catalysed by the enzyme. 
It should be noted that AKR1C3 has enzymatic activities other than just 17βHSD activity. AKR1C3 
also functions as a reductive 20α-hydroxysteroid dehydrogenase (20α-HSDs) which can reduce 
PROG and deoxycoricosterone, thereby reducing their affinities for the PROG and mineralcorticoid 
receptors, respectively (134, 135). In addition to its role in steroid metabolism AKR1C3 functions 
as an 11-keto prostaglandin (PG) reductase, catalysing the conversion of PGD2 to 9α,11β-PGF2 
and PGH2 to PGF2α (135–140).  
The active site which facilitates this reaction is quite flexible which helps to accommodate a diverse 
range of ligands. In the absence of AKR1C3 PGD2 undergoes spontaneous dehydration reactions 
leading to the synthesis of PGJ2. The J series of prostaglandins are ligands for peroxisome 
proliferator-activated receptors (PPARs), or more specifically PPARγ, which has an anti-
proliferation response (139), while PGF2 is pro-inflammatory and leads to increased proliferation 
(135). Thus PGJ2 isoforms such as 15-deoxy-∆12,14 –PGJ2 (15dPGJ2) are anti-inflammatory as well 
as anti-neoplastic and promotes differentiation (135). AKR1C3 expression therefore results in 
increase in the concentration proliferative PGF2 isomers as well as a concomitant decrease in anti-
Enzyme 
Alteration in expression 
level for PCa 
Alterations in expression 
level for CRPC 
Reaction 
direction 
17βHSD1 ↑ 3 fold (125, 126) ↑ 3 fold (122, 126) Weak → Potent 
17βHSD2 ↓ 7 fold (126, 127) - Potent → weak 
17βHSD3 ↑ 31 fold (122, 126) - Weak → Potent 
17βHSD6 ↑ 2 fold (126, 128) - Weak → Potent 
AKR1C1 ↓ 2-4 fold (126, 129–131) ↑ 3 fold (121, 122, 126) Potent → Weak 
AKR1C2 ↓ 16 fold (126, 129–131) ↑ 2-3 fold (121, 122, 126) Potent → Weak 
AKR1C3 ↑ 2-5 fold (126, 127) 
↑ 5-8 fold (112, 121–123, 
126) 
Weak → Potent 
SRD5A1 ↑ 2 fold (121, 126, 132) 
↑ 2-3 fold (112, 121–123, 
126) 
Weak → Potent 
SRD5A2 ↓ 2-4 fold (66, 121, 126, 133) 
↓ 2-9 fold (112, 121–123, 
126) 
Weak → Potent 
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proliferative PGJ2 products and therefore has an impact on hormone dependant as well as 
hormone independent cancers, making AKR1C3 a prevalent drug target (135) (figure 1.14).  
One of the biggest challenges when developing a drug is target site specificity which is 
complicated due to the high sequence homology between members of the AKR family (135). More 
specifically an 84% homology between AKR1C3, AKR1C1, AKR1C2 and AKR1C4 requires the 
drug to be highly specific especially considering that all these enzymes plays a role in steroid 
metabolism. Inhibition of AKR1C1 and AKR1C2 could promote the development of PCa 
considering that they act predominantly as 3-ketosteroid reductases which convert active 
androgens, such as DHT, to inactive metabolites. Inhibition of these enzymes could therefore lead 
to unwanted activation of the AR (135).  
 
Figure 1.14: AKR1C3 as possible drug target. The inhibition of AKR1C3 activity leads to an increase in PPARγ 
receptor response which has an anti-proliferation effect, promoting differentiation. Adapted from: Bauman, D. R., 
Rudnick, S. I., Szewczuk, L. M., Jin, Y., Gopishetty, S., and Penning, T. M. (2004). Mol. Pharmacol. 67, 60 – 68. 
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Studies therefore aim to develop a non-steroidal anti-inflammatory drug (NSAID) analogue which is 
based on known structure activity relationships and which has a high specificity for AKR1C3. 
Inhibitors of AKR1C3 that have been considered to date include mefenamic acid and N-
phenylanthranilic acid (135). While mefenamic acid is more selective towards the AKR1C isozymes 
it was still able to inhibit COX isozymes. On the other hand, N-Phenylanthranilic acid derivatives 
were found to be highly specific towards not only AKR1C3 but also other AKR1C isozymes such as 
AKR1C2 and did not inhibit COX isozymes (141). 
A study by Byrns et al., (142) investigated the inhibitory effect of a number of NSAIDs and 
indomethacin, an AKR1C3 inhibitor, analogues (figure 1.15). Considering structure-activity 
relationships they identified analogues which do not inhibit COX-1, COX-2, AKR1C1, and AKR1C2, 
but still exhibit AKR1C3 inhibition. Based on these results they went on to synthesize N-(4-
chlorobenzoyl)-melatonin (CBM), which did not inhibit COX-1 or COX-2, but was found to inhibit 




17βHSD2 is a microsomal oxidase which utilizes NAD+ to catalyse the inactivation of androgens 
and estrogens (95). 17βHSD2 was first isolated from prostatic and placenta cDNA libraries (143). 
Wu et al. characterized the 1.4-kilobase cDNA encoding the human 17βHSD2. They showed that it 
encoded for a 387-amino acid protein with a predicted molecular weight of 42,782 Da. An amino-
terminal type 2 signal anchor motif was identified as well as a carboxyl-terminal endoplasmic 
reticulum retention motif, the latter suggesting that the enzyme is associated with the membrane of 
the endoplasmatic reticulum. The active site tetrad consist of amino acid residues Asn-Ser-Tyr-Lys 
at positions 111, 138, 151 and 155 respectively (144). Tyr-151 acts as the catalytic base (145) 
Figure 1.15: The hypothesized formation of inhibitory complexes during reactions catalysed by AKR1C3. 
Abbreviations: E, enzyme; I, inhibitor; S, substrate; and P, product. Reproduced with permission from: Byrns, M. C., 
Steckelbroeck, S., and Penning, T. M. (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective 
inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential 
target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75, 484–
493 (142). 
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while the Ser-138 residue stabilizes the substrate. Lys-155 forms hydrogen bonds with the 
nicotinamide ribose moiety which results in a lower pKa value of the Tyr-OH and in turn promotes 
the transfer of protons (144).  
17βHSD2 is responsible for the conversion of T to A4, E2 to estrone (E1) and DHT to 5α-dione. Our 
group has also shown that this enzyme can convert 11KT, 11KDHT and 11K-3α-diol to 11KA4, 
11K-5α-dione and 11KAST, respectively (95). 17βHSD2 has also been found to exhibit low 20α-
hydroxysteroid dehydrogenase activity towards 20α-dihydroprogesterone (95, 143). 17βHSD2 is 
expressed in the endometrium, liver, placenta, small intestine, colon, kidney, pancreas and 
prostate (95, 146, 147). Because of 17βHSD2s widespread tissue distribution and broad substrate 
specificity it is hypothesized that its role in human physiology is to protect tissue from excessive 
exposure to potent steroid hormones (95, 148). No 17βHSD2 deficiencies have been identified yet 
and thus the role of this enzyme is thus not fully understood (95).  
Wu et al. (1993) characterized 17βHSD2 activity towards 7 different substrates including, E2, T, 
DHT, 20-α dihydroprogesterone, E1, A4 and PROG as shown in table 1.4. 
  
Table 1.4 Kinetic constants previously determined for 17βHSD2. Adapted from: Wu, L., Einstein, 
M., Geissler, W. M., and Chan, H. K. (1993) Expression Cloning and Characterization of Human 178- 
Hydroxysteroid Dehydrogenase Type 2 , a Microsomal Enzyme Possessing 20a-Hydroxysteroid 
Dehydrogenase Activity. J. Biol. Chem. 268, 12964–12969. 




E2 0.21 ± 0.04 38 ± 11 181 
T 0.39 ± 0.09 45 ± 15 115 
DHT 0.31 ± 0.11 38 ± 4 123 
20α-DihydroPROG 0.71 ± 0.06 5.6± 0.2 8 
E1 0.78 ± 0.08 6.6 ± 0.2 8 
A4 2.63 ± 0.20 11.5 ± 2 4 
PROG - <0.3 - 
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To the best of our knowledge no kinetic data is currently available for the conversion of 11KT or 
11KDHT by 17βHSD2. In a different study, Wu et al. investigated the optimal temperature and pH 
conditions for 17βHSD2 activity. They found that the enzyme was sensitive to temperature with an 
optimal activity at a temperature of 37°C. Furthermore, the authors found that the enzyme was 
most active at an alkaline pH of 8-10 (143). Research to date has focussed on the expression 
levels of AKR1C3, which is upregulated in CRPC, while overlooking the role of 17βHSD2 in the 
development of this disease, considering that the expression levels of this enzyme seem to either 
remain constant or decrease in CRPC. Very little is known about 17βHSD2‟s role in the 
development of CRPC. 
 
1.6.3. Enzyme ratios 
The flux through steroidogenic pathways can be influenced or controlled by the expression of HSD 
enzymes and their relative activity. In many cases there is one HSD which catalyses and activation 
step, such as the conversion of A4 to T by AKR1C3 (17βHSD5), while another enzyme catalyses 
the reverse inactivation step, such as the conversion of T to A4 by 17βHSD2. Changes in the 
relative expression of these enzymes, as is observed in CRPC, therefore have the potential to 
change the flux through a given pathway.   
An example of a study which tested the effect of HSDs on the flux of a pathway was performed by 
Meittinen et al. (146) who investigated the conversion between E1 and E2 in a human embryonic 
kidney cells (HEK293 cells) transfected with 17βHSD type1 and type 2. 
17HSD1 acts as a reductase converting E1 to E2. In contrast 17HSD2 possesses oxidative activity 
inactivating E2 by converting it to the less potent steroid E1. HEK293 cells transfected with 
17βHSD1 demonstrated a high percentage of conversion of E1 to E2 while no conversion was 
found for the reverse reaction. In HEK293 cells only transfected with 17βHSD2 only the reverse 
reaction was favoured (146). 
Meittinen et al. (146) next investigated the activity of 17βHSD1 and 17βHSD2 in other cell lines 
which similar to HEK293 cells do not endogenously express these enzymes. The cell lines HEC-1-
B, LNCaP and MCF-7 were transiently transfected with 17βHSD1 or 17βHSD2 and E1 and E2 were 
given as substrates. All cell lines transfected with 17βHSD1 showed high levels of E1 to E2 
conversion, while the opposite was observed for cell lines transfected with 17βHSD2. 
Finally, PC3 cells endogenously expressing the type 2 enzyme were transfected with 17βHSD1. 
Untransfected PC3 controls resulted in high levels of conversion from E2 to E1. No conversion from 
E1 to E2 was observed as expected. The addition of type 1 resulted in a dramatic increase in the 
conversion of E1 to E2 and very low levels of conversion from E2 to E1. Next, T-47D, endogenously 
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expressing 17HSD1 was transfected with 17βHSD2. In contrast to PC3 cells, untransfected T-47D 
cells converted E1 to E2 and no conversion of E2 to E1 was observed as expected. When 
transfected with 17βSD2 the same trend is observed compared to transfected PC3 cells. High 
levels of E1 were found to be converted to E2 and low levels of E2 was converted to E1 (146). These 
results emphasize how the ratio of two enzymes, responsible for the interconversion of 
substrate/product, can affect one another.  
The HSD enzymes have been under the spotlight when investigating the development of PCa and 
CRPC because of their direct role in intratumoural androgen metabolism. As mentioned above, 
these enzymes are often considered possible therapeutic targets for the treatment of PCa and 
CRPC. In the classic pathway, AKR1C3 converts A4 to T, while in the 5α-dione pathway it 
catalysis the conversion of 5α-dione to DHT. Finally, in the 11OHA4 pathway AKR1C3 converts 
11KA4 to 11KT as well as 11K5α-dione to 11KDHT. All of these products have been shown to 
activate the AR and are considered to have high androgenic activity. On the other hand, 17βHSD2 
catalyses the reverse reactions, thereby leading to the inactivation these androgens.  
 
1.7. Project Objectives 
 
Changes in the expression levels of these two enzymes are clear during the development of 
CRPC, with AKR1C3 being upregulated (124, 149) and 17βHSD2 levels decreasing or remaining 
constant (127, 150) as discussed earlier in this section, thus favouring androgen production. 
Although it is clear that these enzymes play vital roles in the respective androgen pathways 
(classic, 5α-dione and 11OHA4) a comparison of the contribution of these enzymes to the 
pathways is lacking. The aim of this project was therefore to determine the effect of alterations in 
AKR1C3 and 17βHSD2 expression which mimic intratumoural enzyme expression in CRPC cells, 
on the flux through the intratumoral pathways. Furthermore, we set out to characterise the activity 
of 17βHSD2 towards 11KT and 11KDHT. This study forms part of a larger project in our group, 
which aims to build a comprehensive mathematical model of intratumoural androgen metabolism 
which will account for the classic, 5α-dione and 11OHA4 pathways.  
Specific aims for this study: 
 To develop a high throughput UPC2-MS/MS method for the separation and quantification of 
AKR1C3 and 17βHSD2 metabolites.  
 To characterize the catalytic activity of 17βHSD2 for substrates from the classic, 5α-dione 
and 11OHA4 pathways. 
 To investigate the effect of different AKR1C3 to 17βHSD2 ratios on metabolism of 
metabolites from the classic, 5α-dione and 11OHA4 pathways. 
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 Chapter 2 
Materials and Methods 
 
2.1. Materials  
 
2.1.1. General reagents 
Dulbecco‟s modified Eagles medium (DMEM), HAM‟s F12K, Roswell Park Memorial Institute 
media (RPMI-1640), Ampicillin sodium salt, β-glucuronidase from bovine liver, Diethyl 
pyrocarbonate (DEPC), Dimethyl sulfoxide (DMSO), tert-Buthyl methyl ether (MTBE), 2-Propanol 
and Chloroform were purchased from Sigma Aldrich (St. Louis, MO, USA). Fetal Bovine Serum 
(FBS), Sodium pyruvate and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were 
purchased from BioChrom (Camboume, UK). Penicillin-streptomycin and Trypsin-EDTA were 
purchased from Gibco (Gaithersburg, MD, USA). Wizard® Plus Midipreps DNA Purification 
System, Recombinant RNasin® Ribonuclease Inhibitor, Oligo(dT)15 Primer, dNTP Mix and 
ImProm-II™ Reverse Transcriptase were purchased from Promega (Madison, Wisconsin, USA). 
Restriction endonucleases (SalI, EcoRI) were purchased from Fermentas (Burlington, Canada). X-
tremeGene HP DNA Transfection Reagent was purchased from Roche Diagnostics (Mannheim, 
Germany). Tri Reagent® and KAPA SYBR® FAST qPCR Master Mix for LightCycler® 480 were 
purchased from Zymo Research (Irvine, USA) and KAPA Biosystems (Cape Town, ZAR), 
respectively. Primers for 17βHSD2 and AKR1C3 were purchased from Inqaba Biotec (Pretoria, 
ZAR). The Pierce™ BCA Protein Assay kit was purchased from Thermo Scientific™. Absolute 
Ethanol was purchased from Merck (Darmstadt, Germany) and Methanol was purchased from 
Romil (Cambridge, UK). 
 
2.1.2. Cell lines 
HEK293 and VCaP cells were purchased from the American Type Culture Collections (ATCC) 
(Manassa, VA, USA). LNCaP and PC3 cells were purchased from the European Collection of Cell 
Cultures (ECACC) (England, UK). The C4-2B cell line was a generous gift form Professor D Neal 
(University of Oxford, UK). 
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2.1.3. Plasmids 
A pcDNA3 vector containing AKR1C3, as well as a pcDNA4 vector containing 17βHSD2 were both 
generous gifts from Prof. J. Adamski (Institute of Experimental Genetics, Germany). A pcDNA3 
vector containing AKR1C2 was obtained from Prof. T.M. Penning (University of Pennsylvania, 
Philadelphia, USA). A pCIneo plasmid containing no insert was available for use in the laboratory. 
 
2.1.4. Steroids and inhibitors 
17β-Dihydroandrosterone (5α-androstan-3α,17β-diol; 3α-adiol), Androstanedione (5α-androstan-
3,17-dione; 5α-dione), Androstenedione (androsten-3,17-dione; A4), Androsterone (5α-androstan-
3α-ol-17-one; AST), Dihydrotestosterone (5α-androstan-17β-ol-3-one; DHT), Drospirenone (17-
Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21 carboxylic acid, DRSP), 
Dutasteride ((5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-
carboxamide), Gestodene (4,15-estradien-17β-ethynyl-18-homo-17α-ol-3-one, GES), 
Indomethacin (1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid) and Testosterone (4-
androsten-17β-ol-3-one; T) were purchased from Sigma Aldrich (St. Louis, USA). 11-
Ketoandrostenedione (4-androsten-3,11,17-trione; 11KA4), 11-ketotestosterone (4-androsten-17β-
ol-3,11-dione; 11KT), 11-ketodihydrotestosterone (5α-androstan-17β-ol-3,11-dione; 11KDHT) and 
11-ketoandrosterone (5α-androstan-3α-ol-11,17-dione; 11KAST) were purchased from Steraloids 
(Wilton, USA) and the internal standard testosterone-1,2-d2 (T-d2) was purchased from Cambridge 
Isotope Laboratories (Andover, USA). All steroids, as well as dutasteride were purchased as a 
powder and dissolved in 100% absolute ethanol.  Indomethacin was purchased as a powder and 




2.2.1. Cell Culture 
LNCaP cells were cultured in RPMI-1640 media supplemented with 10% FBS, 1.5 g/L NaHCO3, 
2.5 g/L D-(+)-Glucose, 1% HEPES, 1% sodium pyruvate and 1% penicillin-streptomycin (stock 
containing 10 000 U/mL penicillin and 10 000 μg/mL streptomycin) in 75 cm2 Corning® CELLBIND® 
surface flasks. C4-2B cells were cultured in RPMI-1640 media supplemented with 10% FBS, 
1.5g/L NaHCO3, 2.5 g/L D-(+)-Glucose and 1% penicillin-streptomycin in 75 cm
2 cell culture flasks. 
HEK293 and VCaP cells were cultured in DMEM media supplemented with 10% FCS, 1.5 g/L 
NaHCO3, 1% sodium pyruvate and 1% penicillin-streptomycin in 75 cm
2 Corning® CELLBIND® 
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surface and 75 cm2 cell culture flasks respectively. PC3 cells were cultured in HAMs F12K media 
supplemented with 10% FCS, 1.5 g/L NaHCO3 and 1% penicillin-streptomycin in 75 cm
2 cell 
culturing flasks. All cell lines were grown at 37 °C in 90% humidity and 5% CO2. All cells were 
routinely tested for mycoplasma infection as follows: A sterile coverslip was placed in a 10 cm2 cell 
culture dish and 3 drops of 80% confluent cell suspension was added to the middle of the slip. 
Media (6 mL) was carefully placed around the coverslip without disturbing the cells. Cells were 
then incubated for 4 days and subsequently fixed using methanol:acetic acid in a ratio of 3:1. Cells 
were then covered with Hoechst Stain Working Solution (2 mL) and incubated at room temperature 
for 2 min. A drop of mounting solution was subsequently added to the coverslip after which the 
coverslip was placed, cells facing downwards on a slide. Cells were then viewed at 60x 
magnification using a Live Cell Imaging Microscope (Olympus IX81 epifluorescent microscope, 
DAPI filter set, Shinjuku, Tokyo, Japan). 
 
2.2.2. Plasmid DNA preparations 
JM109 E. coli freezer stocks containing the pcDNA3-AKR1C3, pcDNA3-AKR1C2 and pcDNA4-
17βHSD2 constructs were used to inoculate 100 mL Luria-Bertani (LB) media containing 100 g/mL 
Ampicillin. The cultures were incubated at 37 °C while shaking at 200 rpm for 16 hours (Innova™ 
4000 incubator shaker, New Brunswick scientific). The cultures were subsequently centrifuged at 
10 000 xg for 10 min at 4 °C (Avanti® JE centrifuge). The pellets were collected after which the 
plasmid DNA was purified using Wizard® Plus Midiprep DNA Purification System according to the 
manufacturer‟s instructions. The concentrations of the purified plasmids were determined 
spectrophotometrically using a Cary 60 UV-VIS (Agilent technologies). The identity of the plasmid 
constructs were subsequently confirmed using restriction endonuclease digestion. Restriction 
endonuclease reactions contained 1 μg plasmid DNA, 10 units of the relevant restriction enzyme 
and 2 μL of the appropriate BSA containing buffer (x10). The final reaction volume was 20 μL. The 
reactions were incubated at 37 °C for 1 hour. Digested and undigested samples were analysed 
using 1% agarose gel electrophoresis. Samples were diluted to a concentration of 2 µg in a total 
volume of 20 μL, followed by the addition of 10 μL loading buffer (0.2%) containing: 0.1% Orange 
G (w/v), 20% Ficoll (w/v) and 10 mM EDTA. Electrophoresis was carried out using TAE buffer (40 
mM Tris-acetate, 2 mM EDTA and 20 mM acetic acid). The 1% agarose gel was electrophoresed 
at 110 V for 3 min after which the voltage was decreased to 75 V until the dye was visible as a 
front approximately 1 cm from the bottom of the gel. The gel was subsequently stained using GR 
green® and visualised using Vilber Lourmat UV lamp coupled to a Vidamax camera from Omni-
Science CC (Randburg, South Africa). 
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2.2.3. Determination of kinetic constants using initial rates 
HEK293 were maintained and grown in a 75 cm2 flasks until 80% confluent. Cells were 
subsequently transfected with 17βHSD2 using X-tremeGENE transfection DNA reagent according 
to the manufacturer‟s protocol. Twenty-four hours after transfection the cells were re-plated at a 
density of 5 x 104 cells/well (300 µL) in Corning® CELLBIND® 48 well plates. After re-plating, the 
cells were incubated for a further 24 hours to ensure reattachment. Six different substrates (T, 
DHT, 5α-adiol, 11KT, 11KDHT and 11K5α-adiol) were added to the cells at six concentrations 
each (0.25, 0.5, 1, 5, 10 and 20 μM) and time points (150 µL) were collected every 10 min for a 
total of 40 min for substrate concentrations ≤ 1 μM and every 15 min for a total of 60 min for 
substrate concentrations > 1 μM. 
2.2.3.1. Determination of a response factor for 11K-5α-dione 
A standard for the steroid 11K-5α-dione was not commercially available. This steroid was therefore 
quantified relative to the standard curve obtained for the parent compounds by making use of a 
response factor which was determined as follows: HEK293 cells were transfected with 17βHSD2 
or the pCIneo vector, containing no insert, as described above. After 72 hours 0.1, 1 and 10 µM 
11KDHT was added to the 17βHSD2 transfected cells. The steroid was also added to the pCIneo 
transfected cells. The samples were collected after 48 hours of incubation which allowed for the full 
conversion of substrate to product. d9-PROG (15 ng) and d2-T (15 ng) were added to the samples 
prior to extraction as describe in section 2.2.6.1 below. The samples were subsequently analysed 
by Ultra performance convergence chromatography tandem mass spectrophotometry (UPC2-
MS/MS) to verify if all the substrates had been fully converted to their respective products in the 
case of and 17βHSD2 transfected cells and to confirm that no conversion of substrate to product 
occurred in the cells transfected with pCIneo. The response factor was subsequently calculated as 
follows: the peak area of the substrate was divided by the peak area of the internal standard. The 
ratio of substrate peak area/internal standard peak area (from the pCIneo control) was then divided 
by the ratio of product peak area/internal standard peak area (from the 17βHSD2 conversions) to 
determine the response factor (RF) using the following formula: 
 
As/Ais= RF (Ap/Ais) 
Where: As = area of substrate peak, Ais = area of internal standard peak, Ap = area of product peak. 
 
This calculation was performed for eight replicates for all three steroid concentrations and the 
average response factor calculated.  
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2.2.3.2. Protein determination 
After media was removed for steroid extraction cells were washed twice with phosphate buffered 
saline (PBS) after which 50 μL passive lysis buffer (0.2% (v/v) Triton, 10% (v/v) glycerol, 2.8% (v/v) 
TRIS-phosphate-EDTA and 1.44 mM EDTA) was added to the cells. The cells were mixed for 15 
min and then frozen at -20 °C until. The cell lysate was thawed and the protein concentration 
determined using a Thermo Scientific™ Pierce™ BCA Protein Assay kit according to the 
manufacturer‟s protocol.  
For progress curve analysis HEK293 cells were transfected with 17βHSD2 and re-plated as 
described above (section 2.2.3). Three different concentrations (0.1, 1 and 10 μM) of T and 11KT 
were added as substrates to a total volume of 500 µL. Time points (150 µL) were collected at 20, 
40, 60, 90, 120, 150, 180, 210, 240, 270, 300 and 360 min. 
 
2.2.4. Ratio experiments 
2.2.4.1. HEK293 ratio experiments 
HEK293 cells were cultured and grown to 80% confluence in Corning® CELLBIND® surface 75 cm2 
flasks. The cells were subsequently transfected with 17βHSD2, AKR1C3 or pCINeo using X-
tremeGENE transfection DNA reagent. After twenty-four hours the cells were counted and 
combined in different ratios of 17βHSD2:AKR1C3 as shown in table 2.1 before re-plating in 
Corning® CELLBIND® surface 24 well plates at a density of 2.1 x 105 cells per well (500 µL). Cells 
transfected with the pCINeo plasmid, which contained no insert, were used to ensure all ratios 
contained an equal number of cells.  
After 24 hours the media was removed and replaced with full media (supplemented with 10% FBS 
and 1% PenStrep) with a final volume of 500 µL, containing 1 μM or 0.1 μM of the steroid 
substrates A4, 11KA4 and 5α-dione or a combination of A4 and 11KA4, respectively. Time points 
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Table 2.1: Summary of the HEK293 ratios experiment. HEK293 cells transfected with 17βHSD2 










Additional ratio experiments (0:1, 1:1, 1:4 and 1:6) were performed as described above, but 
included the addition of the AKR1C3 inhibitor Indomethasin (50 μM). An equivalent amount of 
DMSO was added to all wells which did not contain Indomethasin. 
2.2.4.2. Ratio experiment validation 
A mathematical model for the conversion of A4 and 11KA4 by different ratios of 
AKR1C3:17βHSD2 was constructed using the kinetic parameters for 17βHSD2 determined by this 
study as well as the kinetic parameters for AKR1C3 determined by our group (unpublished data). 
These parameters are listed in table 3.4, section 3.4.2. The model was constructed by Prof JL 
Snoep (Department of Biochemistry, University of Stellenbosch) using Mathematica (Wolfram). 
2.2.4.3. PC3 Ratio experiments 
PC3 cells were maintained and grown to 80% confluence in 75 cm2 flasks and subsequently plated 
in 12 well plates at a density 2 x 105 cells/well (1 mL). After 24 hours the cells were transfected with 
a total of 1 μg plasmid DNA per well. DNA was made up of 0 μg, 0.25 μg, 0.5 μg or 1 μg of the 
AKR1C3 plasmid. The pCINeo plasmid, which contained no insert, was used to ensure that the 
cells were transfected with an equal amount of DNA, as shown in table 2.2. Transfections were 










1:0 3 x 104 0 1.8 x 105 2.1 x 105 
0:1 0 3 x 104 1.8 x 105 2.1 x 105 
1:1 3 x 104 3 x 104 1.5 x 105 2.1 x 105 
1:3 3 x 104 9 x 104 9 x 104 2.1 x 105 
1:4 3 x 104 1.2 x 105 6 x 104 2.1 x 105 
1:5 3 x 104 1.5 x 105 3 x 104 2.1 x 105 
1:6 3 x 104 1.8 x 105 0 2.1 x 105 
0:0 0 0 2.1 x 105 2.1 x 105 
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Table 2.2: Summary of the PC3 ratio experiment. PC3 cells, which 
endogenously express 17βHSD2, were transfected with increasing amounts 
of AKR1C3. 
AKR1C3 added (μg) pCINeo added (μg) 
Total DNA 
added (μg) 
0.00 1.00 1.00 
0.25 0.75 1.00 
0.50 0.50 1.00 
1.00 0.00 1.00 
 
Seventy-two hours after transfection the media was replaced with fresh media (1 mL) containing 
0.1 μM of the steroid substrates (A4, 11KA4, T and 11KT) and 10 μM dutasteride, a SRD5A1/2 
inhibitor. Time points (500 µL) were collected 24 hours after substrate addition. Samples were 
stored at 4 °C until further analysis. Media was removed and 400 μL Tri-Reagent® was added to 
each well. Cells were frozen at -80 °C until RNA isolation.  
The potential effect of dutaseride on the activity of AKR1C3 and 17βHSD2 was tested in HEK293 
cells transiently transfected with plasmids expressing these enzymes using X-tremeGENE 
transfection DNA reagent according to the manufacturer‟s protocol. AKR1C3 activity was assayed 
using 0.1 μM and 1 µM A4 or 11KA4 as substrates, while 17βHSD2 activity was assayed using 0.1 
μM and 1 µM T or 11KT. Assays were conducted in the presence as well as the absence of 10 μM 
dutasteride. Time points (250 µL) were collected every 10 min for a total of 50 min. 
 
2.2.5. Time courses in PCa cell lines 
VCaP and C4-2B cells were grown and maintained in 75 cm2 flasks while LNCaP cells were 
cultured in Corning® CELLBIND® surface 75 cm2 flasks. Cells were plated in 24 well plates at cell 
density of 1 x 105 cells/well (500 µL) for VCaP cells and 2.5 x 104 cells/well (500 µL) for C4-2B and 
LNCaP cells. After 24 hours the media was replaced with media containing 0.1 μM A4, 11KA4, T 
or 11KT respectively as well as 10 μM dutrastride. Time points (500 µL) were collected every 24 
hours for a total of 4 days. Samples were deconjugated prior to extraction. The pH of samples was 
set to 6.5 using 1% acetic acid. To each sample, 800 units of β-glucuronidase from bovine liver 
were added after which the samples were incubated at 37 °C for 24 hours. DHT and DHT-G were 
made up in RPMI 1640 media to a concentration of 1 µM. One of each was deconjugated and 
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used as a positive control. Internal standards d2-T, GES and DRSP were added to each sample 
and steroids were extracted as described in section 2.2.6.1 below. 
 
2.2.6. Samples preparation and analysis by UPC2-MS/MS 
2.2.6.1. Steroid extraction 
Steroids were extracted from media using MTBE at a ratio of 3:1 (MTBE:media). The samples 
were shaken for 10 min, allowed to stand for 5 min and then incubated at -80 °C for an hour to 
allow the aqueous layer to freeze. The MTBE layer containing the steroids was subsequently 
transferred to a clean test tube and evaporated under a stream of nitrogen gas (N2). Samples were 
then re-suspended in 50% methanol and stored at -20 °C prior to analysis by UPC2-MS/MS. A 
volume of 150 μL was used to resuspend samples from experiments where substrate 
concentrations ≤ 1 μM were used, while samples from experiments where substrate concentrations 
> 1 μM were resuspended in 1 mL.  
2.2.6.2. Sample analysis 
Steroids were separated using an ACQUITY UPC2 system (Waters Corporation, Milford, USA) with 
an ACQUITY UPC2 BEH 2-EP column (3 mm X 100 mm, 1.7 µm particle size) as previously 
reported (151). Supercritical CO2 was used as the primary mobile phase and was combined with 
methanol which was used as an organic modifier. The gradient profile for the 5 min run is shown in 
table 2.4. The flow rate was kept constant at 2.0 mL/min and the column temperature and 
automated back pressure regulator (ABPR) were set to 60 °C and 2000 psi, respectively. The 
injection volume was 2 µL for all standards and samples. A make-up pump was set to feed 1% 
formic acid in methanol at a constant flow rate of 0.2 mL/min to the mixer preceding the MS line. A 
Xevo TQ-S triple quadruple mass spectrometer (Waters, Milford, USA) was used for quantitative 
mass spectrometric detection. Multiple reaction monitoring (MRM) was used to analyse all steroids 
with a positive ionization mode electrospray probe (ESI +). Data was collected and analysed using 
MassLynx 4.1 (Waters Corporation). The capillary voltage was set to 3.8 kV and the source and 
the desolvation temperature was set to 120 °C and 500 °C respectively, while the desolvation and 
cone gas were set to a flow rate of 1000 L/h and 150 L/h, respectively. 
 
 
Table 2.3: MRM mass transitions and mass spectrometer parameters. Parameters for the detection and quantification of 
C19 steroids by UPC2-MS/MS: retention time (RT) for a (RTA) 5 min inlet method as well as a (RTB) 2.5 min inlet method; 
cone voltages (CV); collision energy (CE). 
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5α-dione 289.18 253.14 22 16 97.2 30 22 0.52 0.46 
A4 287.2 96.9 30 15 108.8 30 15 0.68 0.75 
11K5α-dione 303.2 241 35 30 267 35 25 0.96 - 
11KA4 301.2 257 35 25 265.2 35 25 1.07 1.08 
DHT 291.22 255 25 15 273 25 20 1.16 0.98 
AST  273.2>105.4 30 30 291.3>273.3 18 8 1.16 - 
T 289.2 97.2 30 22 109 30 22 1.53 1.44 
11KAST 305 147.2 30 30 173.1 30 30 1.56 - 
11KDHT 305.2 23 30 20 269 30 20 1.84 - 
5α-adiol 275.5 257 15 15 175 15 15 2.08 - 
11KT 303.2 121 30 20 267 30 20 2.24 2.03 
11K5α-adiol 307.2 271 15 10 253 15 10 3.16 - 
  
d9-PROG 324.2 100 30 20 113 30 25 0.65 - 
d2-T 291 99.1 30 20 111.2 30 30 1.53 - 
GES 311.2 109.4 15 25 135 15 25 1.63 - 
DRSP 367.2 97.3 20 30 159.3 20 25 1.82 - 
Step Time (min) 
Flow rate 
(mL/min) 
% Solvent A % Solvent B Curve 
1 Initial 2 99 1 Initial 
2 4 2 91 9 7 
3 4:10 2 75 25 6 
4 5 2 99 1 6 
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Table 2.5: Binary solvent manager inlet gradient for a 2.5 min method on the UPC
2
-MS/MS. 
Step Time (min) 
Flow rate 
(mL/min) 
% Solvent A % Solvent B Curve 
1 Initial 2 96 4 Initial 
2 1.5 2 92 8 6 
3 1.6 2 75 25 6 
4 2.5 2 96 4 6 
  
 
Samples collected from kinetic experiments were analysed using a 5 min method developed to 
separate 19 C19 steroids (151) (table 2.4). Samples containing only A4, T, 11KA4, 11KT, 5α-dione 
and DHT were separated using a 2.5 min method as shown in table 2.5. All other settings were as 
described above. 
 
2.2.7. qPCR  
2.2.7.1. RNA isolation  
Total RNA was isolated using Tri® Reagent. Cells were allowed to thaw in the Tri® Reagent and 
were lysed by pipetting. The mixture was then transferred to a 1.5 mL RNA free microcentrifuge 
tube. The samples were incubated at room temperature for 5 min prior to the addition of 80 μL 
chloroform. The samples were then vortexed to mix the content after which they were incubated at 
room temperature for an additional 3 min. Samples were subsequently centrifuged at 13 000 rpm 
using the Biofuge® fresco (Heraeus, Germany) for 30 min at 4 °C. The aqueous phase was then 
moved to a new 1.5 mL RNA free microcentrifuge tube followed by the addition of an equal volume 
of isopropanol. The samples were mixed by vortexing and then incubated at room temperature for 
15 min. Samples were centrifuged at 13 000 rpm for 20 min at 4 °C after which the supernatant 
was removed and the pellet washed with 500 μL 75% ethanol. Samples were subsequently 
vortexed and centrifuged at 8000 rpm at 4 °C for 10 min. The supernatant was removed and 
samples were centrifuged again at 8000 rpm for 5 min. The pellet was then air dried for 10 min on 
ice and then re-suspended in 15 μL DEPC treated water. RNA concentration was measure using a 
Nanodrop 200 spectrophotometer from Thermo Scientific™ (Waltham, Massachusetts, US). 
Samples were stored at -80 °C until use.  
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2.2.7.2. cDNA synthesis 
The GoScript™ Reverse Transcription System kit was used for first strand cDNA synthesis 
according to the manufacturer‟s protocol. The following components were added and mixed in the 
order as listed in table 2.6 below: 
 
Table 2.6: RNA and Primer mix components 
 for cDNA synthesis. 
Component Volume 
Experimental RNA 0.5 μg 
Oligo(dT)15 primers 1 μL 
Nuclease-free water Up to 5 μL 
Total 5 μL 
 
The samples were incubated on a heating block at 70 °C for 5 min after which they were 
immediately placed on ice for 5 min. Samples were then vortexed for 10 seconds and stored on ice 
while the rest of the components were prepared. The reverse transcription reaction mix was 
prepared as shown in table 2.7 below. 
 
Table 2.7: Components of the reverse transcriptase mix. Volumes are shown per reaction. 
Component Volume 
GoScript™ 5X Reaction Buffer 4.0 μL 
MgCl2 (final concentration, 1.5-5.0 mM) 1.2-6.4 μL 
PCR Nucleotide Mix (final concentration 0.5 mM each 
dNTP)2 
1.0 μL 
Recombinant RNasin® Ribonuclease Inhibitor 20 units 
GoScript™ Reverse Transcriptase 1.0 μL 
Nuclease free water Up to 15 μL 
Final volume 15 μL 
 
The prepared reverse transcriptase mix was added to the template and primer mix and the 
reactions were incubated at 25 °C for 5 min and then at 42 °C for one hour. Reactions were 
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subsequently stopped by incubation at 70 °C for 15 min. Samples were stored at -20 °C until 
further use. 
2.2.7.3. Primers  
Primers for the relative quantification of 17βHSD2 and AKR1C3 were selected from literature. 
Primers for the amplification of the reference gene ALAS (delta-aminolevulinate synthase) were 
previously aselected from literature and were available for use in the laboratory (107). Primer 
sequences are shown in table 2.8. 
 
Table 2.8: List of all qPCR primer sequences  
 
2.2.7.4. PCR optimisation 
Real-time PCR was performed using the KAPA SYBR® FAST qPCR Master Mix for LightCycler® 
and a LightCycler® 96, rapid thermal cycler instrument (Roche Life Science). Each qPCR reaction 
mixture was prepared as shown in table 2.9 below.  
The qPCR profile consisted of a pre-incubation at 95 °C for 3 min followed by amplification which 
consisted of: denaturation at 95 °C for 10 seconds; primer annealing using a temperature gradient 
(50-62 °C) for 20 seconds; and extension at 72 °C for 1 second. Forty-five cycles were typically 
used for amplification and was followed by melting curve analysis. Melting curve analysis was 
performed by denaturing the samples at 95 °C for 5 seconds followed by annealing at 65 °C for 60 
seconds.  The samples were then heated from 65 °C to 97 °C at a ramp rate of 2.2 °C per second.   
 
Primer Oligonucleotide sequence (5′ → 3′) References 
17βHSD2 (forward) TCTTTGGAACTGTGGAGGTCACAAAGACGT (152) 
17βHSD2 (reverse) AGAGAAGTCCTTGCTGGCTAACGAGTTGAT  
AKR1C3 (forward) AGCCAGGTGAGGAACTTTC (138) 
ACR1C3 (reverse) ATCACTGTTAAAATAGTGGAG  
ALAS (forward) TTCCACAGGAGCCAGCATAC (107) 
ALAS (reverse)  GGACCTTGGCCTTAGCAGTT  
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Table 2.10 contains the melting temperatures and GC content for each primer set from both the 
synthesis report as well as the Primer-BLAST search. A temperature gradient of 50-62 °C was 
used to determine the ideal annealing temperature for each primer set and the optimal annealing 
temperatures are shown in table 2.10. 
 
Table 2.10:  Summary of theoretical melting temperatures and experimentally determined annealing temperatures 



















67.81 46.67 67.37 46.67 60  
17βHSD2 
(reverse) 
67.38 46.67 67.37 46.67 60  
AKR1C3 
(forward) 
56.96 52.63 60.16 52.63 58  
AKR1C3 
(reverse) 
50.59 33.33 54.76 33.33 58  
ALAS 
(forward) 
62.45 55.00 59.96 55.00 60  
ALAS 
(reverse) 
62.45 55.00 59.96 55.00 60  
Components Volume 
PCR grade water 1μL 
Primer Forward (5 μM stock) 1μL 
Primer Reverse (5 μM stock) 1μL 
KAPA SYBR® FAST qPCR Master Mix 
(2X) 
5μL 
cDNA template 2μL 
Total 10μL 
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2.2.7.5. PCR efficiencies 
PCR efficiencies were determined by using a serial dilution of cDNA template prepared in nuclease 
free water. Standard curves for each primer set were then generated by plotting the cycle threshold 
(Ct) values against the log of the cDNA starting concentrations. The efficiency was then calculating 
using the gradient of the standard curves generated using the formula shown below:  
 
           (  
( 
 
     
  )
  )    
 
2.2.7.6. Relative qPCR quantification 
Optimized parameters and qPCR efficiencies were used to perform relative quantification. A 
reference gene was used to determine relative target gene expression. This was done using a 
modified form of the model constructed by Pfaffl (153) which takes into account the differences in 
PCR efficiencies. Inter-experimental variation was accounted for by applying mean-centering (154) 
to the data which was represented as fold change over the control. 
 
       
                                         
                                      
 
The b values are a representation of the y-intercept of the standard curve generated for each 
primer set using a dilution series.  
 
2.2.8. Statistical analysis 
All data manipulations, graphical representations and statistical analysis were performed using 
GraphPad Prism® software (Version 4). Linear regression was used to determine the initial rates 
for kinetic data. Resulting initial rates were plotted against the respective substrate concentrations 
using the Michaelis Menten equation. qPCR data was processed as described 2.2.7.6. and 
subsequently analysed using one-way ANOVA followed by Tukey‟s multiple comparisons test. 
Data from all ratio experiments were analysed using one-way ANOVA followed by Tukey‟s multiple 
comparisons test. The effect of inhibitors on steroid metabolism was analysed using Student's t 
tests.  
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 Chapter 3 
Results 
 
3.1. Quantitative PCR 
 
3.1.1. Primer design 
Primer sequences for the relative quantification of AKR1C3 (138) and 17βHSD2 (127) by qPCR 
were obtained from literature. Primer sequences were subjected to analysis by Primer-BLAST to 
confirm that each primer annealed in different exons (figure 3.1) as to ensure that genomic DNA 
would not be amplified due to the presence of large intron sequences. A primer set for the relative 
quantification of the reference gene, ALAS, was previously designed by our group and was 
available for use in the laboratory (115).  
 
Figure 3.1 Primer-BLAST analysis of (A) 17βHSD2 and (B) AKR1C3 primers. All primers were shown to bind in 
different exons, thus preventing the amplification of genomic DNA. 
 
3.1.2. Primer optimization 
The optimal annealing temperature for each primer set was determined (figure 3.2, red line) using 
a gradient PCR. Amplifications yielding only a single product as determined by melting curve 
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dimers could not be eliminated completely. An optimal annealing temperature of 60 °C was 
determined for 17βHSD2 and ALAS, while the optimal annealing temperature for AKR1C3 was 
found to be 58°C.  
 
Figure 3.2: Melting curves for 17βHSD2 and AKR1C3. Example of melting curve analysis of 17βHSD2 (A) and 
AKR1C3 (B) primer sets at two different annealing temperatures. Nonspecific amplicons and/or primer dimers can be 
observed as a peak to the left of the amplified product. 
 
3.1.3. qPCR efficiency  
A serial dilution (X2) series of template cDNA was used to determine the qPCR efficiency for each 
primer set. A single qPCR reaction was performed for each dilution. The resulting Ct values were 
subsequently plotted against the log of the cDNA concentration (figure 3.3). The resulting gradients 
from linear regression analysis were used to determine the qPCR efficiencies (table 3.1), which 
were all found to be equal to or above 91%: 17βHSD2, 91%; AKR1C3, 96%; and ALAS, 91%. 
 






Primer set Slope Efficiency (%) 
17βHSD2 -3.5578 91 
AKR1C3 -3.4116 96 
ALAS -3.5511 91 
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Figure 3.3: Calibration curves for 17βHSD2, AKR1C3 and ALAS. The gradients were used to determine the qPCR 




3.2. High throughput UPC2-MS/MS method development 
 
A high throughput UPC2-MS/MS method for the separation and quantification of nineteen C19 
steroids was previously developed in our laboratory (151). As the majority of experiments 
conducted in this study required only the separation and quantification of 6 of these steroids, this 
method was modified to further increase the throughput for this study. Six structurally related C19 
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3.3. The characterisation of 17βHSD2 activity 
 
Figure 3.4: (A) The separation profile of six C19 steroids by UPC
2
-
MS/MS. The elution order is as follows: 5α-dione (1), A4 (2), DHT (3), T (4), 
11KA4 (5) and 11KT (6).  (B) The structures of six C19 steroids separated 
on the UPC
2
-MS/MS in 2.5 min. The order is as follows: 5α-dione (1), A4 (2), 











1 2 3 4 5 6
Time (min)
%
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Since the activity of 17βHSD2 towards 11-oxygenated C19 steroids has not previously been 
characterised, we set out to determine the apparent Km (Km, app) and apparent Vmax (Vmax, app) values 
using the 11-oxygenated steroids 11KT and 11KDHT as substrates. The classical steroids T, DHT 
and 5α-adiol were included in all experiments for comparative purposes. The response factor used 
to quantify 11K-5α-dione, which was not available commercially, is shown in table 3.2.   
 







0.188 ± 0.01 
 
Initial rates (V0) were determined for six substrate concentrations per steroid (figure 3.5) and were 
subsequently used to determine the Km, app and Vmax, app values. V0 was plotted against the 
respective substrate concentrations and a Michaelis Menten equation was fitted using non linear 
regression. The resulting Michaelis Menten fits are shown in figure 3.6 and the respective kinetic 
parameters are summarized in table 3.3. 
It is clear from the kinetic parameters summarized in table 3.3, that 17βHSD2 tended to have the 
highest affinity for DHT (Km, app = 3.18 ± 0.48 µM) closely followed by T (Km, app = 3.35 ± 0.81 µM) 
and 5α-adiol (Km, app = 3.39 ± 0.94 µM). Overall the affinity of 17βHSD2 for the 11-oxygenated C19 
substrates tended to be lower than for the classical C19 steroids, however, these differences were 
not statistically significant. For example, a 69% lower affinity was observed for 11KT (Km, app = 
5.48 ± 1.13 µM) when compared to the affinity of 17βHSD2 for T. The affinity of 17βHSD2 for 
11KDHT (Km, app = 20.46 ± 3.56 µM) was also significantly lower than that of DHT (Km, app = 3.18 ± 
0.48). It should, however, be noted that the Km, app for 11KDHT is only an estimate given the fact 
that no commercial standards were available for the product 11K-5α-dione and analyses therefore 
relied on a response factor which may have introduced additional error into the data. 
Interestingly, despite differences in affinities, no significant difference was found for the Vmax values 
for T (Vmax, app = 131 ± 9.52 µmol/hour/mg protein) and 11KT (Vmax, app = 143 ± 10.2 µmol/hour/mg 
protein). The Vmax, app value for 5α-adiol (Vmax, app = 136 ± 11.4 µmol/hour/mg protein) was also 
similar to that of T and 11KT. 17βHSD2 had a substantially lower Vmax value for DHT (Vmax, app = 
87.3 ± 3.97 µmol/hour/mg protein) compared to that of the other substrates. Conversely, a high 
Vmax value (Vmax, app = 491 ± 50.7 μmol/hour/mg protein) was observed for 11KDHT although the 
accuracy of this needs to be confirmed.    
Stellenbosch University https://scholar.sun.ac.za 
 
 
   51 
 
 



























































































































Figure 3.5 Initial rates for the conversion of (A & B) T to A4, (C & D) 11KT to 11KA4, (E & F) DHT to 5α-dione, (G 
& H) 11KDHT to 11K5α-dione and (I & J) 5α-adiol to AST by HEK293 cells expressing 17βHSD2. Steroids were 
extracted and measured by UPC
2
-MS/MS.  Linear regression lines were fitted in GraphPad Prism. The results are from 
a single experiment performed in triplicate and are expressed as the mean ± SD. 
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Figure 3.6: Michaelis-Menten plots for the metabolism of (A) T, (B) 11KT, (C) DHT, (D) 11KDHT and (E) 5α-adiol 
by 17βHSD2.  
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The catalytic efficiency (Kcat/Km) could not be calculated as the enzyme concentration could not be 
determined. However, all kinetic data was generated during a single experiment in which cells 
were mixed after transfection. It can therefore be assumed that enzyme concentration was 
constant for all substrates and time points and as such catalytic efficiency can be approximated by 
the Vmax/Km values. The highest Vmax/Km values were determined for the conversion of 5α-adiol 
(Vmax/Km = 40.1) and T (Vmax/Km = 39.1). The Vmax/Km values for DHT, 11KT and 11KDHT were all 
similar (27.5, 26.1 and 24.0 respectively). This data shows that the conversion of T to A4 and 5α-
adiol to AST are the most favoured reactions by catalysed 17βHSD2, but that 17βHSD2 can also 
efficiently catalyse the conversion of the 11-oxygenated steroids 11KT and 11KDHT.  
 
Table 3.3: The apparent kinetic parameters (Km, app and Vmax, app) for 17βHSD2.  Letters a and b represents significant 
differences between samples (p>0.05), while values which do not significantly differ are assigned the same letter. 
 
 
The difference in the estimated catalytic efficiency for T and 11KT could clearly be observed during 
time courses conducted with three different concentrations of substrate. Figure 3.7 shows the 
conversion of T and 11KT to their respective products, A4 and 11KA4 by HEK293 cells expressing 
17βSHSD2. Preliminary experiments (results not shown) indicated full conversion of both 
substrates T and 11KT after 6 hours, thus the conversion of T and 11KT to their respective 
products was determined at 20, 40, 60, 90, 120, 150, 180, 210, 240, 270, 300 and 360 min. After 
the first 20 min 56% of the 0.1 µM T was converted to A4 while in the same period of time only 
33% of 11KT was converted to 11KA4. Similar for 1 µM substrates, 91% of T was converted to A4 
in one hour compared to 66% of 11KT converted to 11KA4 in the same period of time. The same 




















T A4 3.35 ± 0.81 a 131  ±  9.52 a 39.1 
11KT 11KA4 5.48 ± 1.13 a 143  ±  10.2 a 26.1 
DHT 5α-dione 3.18 ± 0.48 a 87.3  ±  3.97 a 27.5 
11KDHT 11K5α-dione* 20.46 ± 3.56 b 491  ±  50.7 b 24.0 
5α-adiol AST 3.39 ± 0.94 a 136  ±  11.4 a 40.1 
*No commercial steroids available, calculated using a response factor. 
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Figure 3.7: Time courses for the conversion of T and 11KT by 17βHSD2. Time course for the metabolism of T and 
11KT at (A & B) 0.1 µM, (C & D) 1 µM and 10 μM (E & F) by 17βHSD2 expressed in HEK-293 cells. The results are from 
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3.4. The effect of different AKR1C3:17βHSD2 ratios on steroid metabolism 
 
It is well known that AKR1C3 catalysis the 17β-reduction of A4 to T. Previous studies in our 
laboratory have also shown that the 11-oxygenated steroid 11KA4 is also a substrate for this 
enzyme and that 11KA4 may in fact be the preferred substrate (107, 108). Our group subsequently 
showed that the product of this reaction, 11KT, is an androgen and is equipotent to T (115). 
AKR1C3 expression has been shown to be upregulated in CRPC while the expression of 
17βHSD2, which catalyses the reverse reaction, decreases or remains unaltered, thus leading to 
an increase in the pool of potent androgens (121–124). We therefore hypothesized that given the 
apparent preference of AKR1C3 for 11KA4 an increase in the expression of AKR1C3 will result in 
higher levels of 11KT being produced than T and that this effect would be further enhanced by the 
preference of 17βHSD2 for T as substrate. We therefore investigated this by measuring the effect 
of AKR1C3/17βHSD2 ratios in nonsteroidogenic HEK293 cells and the PCa cell line PC3 on the 
metabolism of A4 and 11KA4. 
 
3.4.1. AKR1C3:17βHSD2 ratios in HEK293 cells 
Nonsteroidogenic HEK293 cells were transfected with AKR1C3, 17βHSD2 and pCINeo, 
respectively and subsequently mixed to obtain different ratios of AKR1C3 to 17βHSD2 while 
keeping the total number of transfected cells constant. The metabolism of A4 and 11KA4 were 
then assayed using two different substrate concentrations (1 μM and 0.1 μM). 
After 24 hours, cells expressing only AKR1C3 (1:0) converted only 2% of the 1 μM A4 to T while in 
the same time 14% 11KA4 was converted to 11KT, confirming previous observations that 11KA4 is 
the preferred substrate as shown in figure 3.8. Cells transfected with only 17βHSD2 (0:1) were 
given T and 11KT as substrate in order to confirm the expression and activity of this enzyme 
(figure 3.8, insert). A negative control (0:0) consisting of only cells transfected with the pCINeo 
vector, which contained no insert, was included in all experiments and confirmed that the HEK293 
were nonsteroidogenic. 
No difference was observed on the amount of A4 converted to T when cells expressing AKR1C3 
and 17βHSD2 were combined in different ratios (figure 3.8A). In contrast, increased ratios of 
AKR1C3 to 17βHSD2 resulted in increased levels of 11KT being produced. The amount of 11KT 
produced increased significantly from 10% at a 1:1 ratio to 30% at a ratio of 6:1 (figure 3.8B). 
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Figure 3.8: The metabolism of 1 μM A4 (A) and 11KA4 (B) by different ratios of HEK293 cells expressing AKR1C3 
and 17βHSD2. Steroids were extracted and measured by UPC
2
-MS/MS. The results are from two independent 
experiments performed in triplicate and are expressed as the means ± SEM. Letters a, b, c and d represents significant 
differences between samples (p>0.05), while values which do not significantly differ are assigned the same letter. 
 
Repeating these experiments using a 0.1 μM substrate yielded similar to results to the experiments 
with 1 μM substrate described above. Increased ratios of AKR1C3 to 17βHSD2 had no effect on 
the production of T, but resulted in significantly higher levels of 11KT being produced as seen in 
figure 3.9A and figure 3.9C respectively. In the alternative 5α-dione pathway A4 is converted to 5α-
dione by SRD5A1, which is in turn converted to DHT by AKR1C3. This route completely bypasses 
the production of T and is believed to be the main contributor to the intraprostatic androgen pool 
after ADT. We therefore also investigated the effect of different AKR1C3 to 17βHSD2 ratios on the 
conversion of 5α-dione to DHT. Similar to the conversion of A4 to T, the conversion of 5α-dione to 
DHT remained low even with an increase in AKR1C3 levels. No significant change in conversion 
was found for any of the ratios (figure 3.9B).  
As there was no difference between the results obtained for T and 5α-dione and as AKR1C3 
catalyses the conversion of A4 and 5α-dione with similar efficiencies (unpublished data) and 
17βHSD2 catalyses the conversion of T and DHT with similar efficiencies (table 3.3), all further 
experiments were carried out with T.   
We subsequently confirmed that the increase in 11KT production observed above was due to the 
increase in AKR1C3 expression. Three different ratios of cells expressing AKR1C3 and 17βHSD2 
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Indomethacin (figure 3.10). Indomethacin had little effect on the already low conversion of A4 to T, 




Figure 3.9: The metabolism of 0.1 μM A4 (A), 5α-dione (B) and 11KA4 (C) by different ratios of HEK293 cells 
expressing AKR1C3 and 17βHSD2. Steroids were extracted and measured by UPC
2
-MS/MS.  Results are shown as 
means ± SEM of three independent experiments performed in triplicate. Letters a, b, c and d represents significant 
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Figure 3.10: The metabolism of 0.1 μM A4 (A) and 11KA4 (B) by different ratios of HEK293 cells expressing 
AKR1C3 and 17βHSD2 in the presence (inh) or absence (DMSO) of the AKR1C3 inhibitor, Indomethacin. Steroids 
were extracted and measured by UPC
2
-MS/MS. Results are from a single experiment performed in triplicate and is 
expressed as the mean ± S D. Statistically significant differences are indicated by *, ** or *** for p<0.05, p<0.01 or 
p<0.001, respectively. 
In vivo, enzymes are exposed to more than one substrate at a time. We therefore assessed the 
simultaneous metabolism of 0.1 μM A4 and 0.1 μM 11KA4 using different ratios of HEK293 cells 
expressing AKR1C3 and 17βHSD2 as described above. 
Figure 3.11: The metabolism of 0.1 μM A4 (A) and 11KA4 (B) by different ratios of HEK293 cells expressing 
AKR1C3 and 17βHSD2. Cells were incubated simultaneously with both substrates. Steroids were extracted and 
measured by UPC
2
-MS/MS.  Results are from three independent experiments each performed in triplicate and are shown 
as the means ± SEM. Letters a, b, c and d represents significant differences between samples (p>0.05), while values 
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A similar pattern was observed as when the substrates where added individually (figure 3.11). The 
conversion of A4 to T remained relatively constant even when AKR1C3 levels increased, while 
increased levels of 11KT were observed as the ratio of AKR1C3:17βHSD2 increased. These 
results show that even in the presence of both substrates an increase in AKR1C3 levels with 
constant levels 17βHSD2 strongly favours the conversion of 11KA4 to the potent androgen 11KT.
  
3.4.2. Model of AKR1C3:17βHSD2 ratios 
A mathematical model for the conversion of A4 and 11KA4 by different ratios of 
AKR1C3:17βHSD2 was constructed in Mathematica (Wolfram). The model was based on the 
kinetic parameters for 17βHSD2 determined by this study as well as the kinetic parameters for 
AKR1C3 determined by our group (unpublished data). As Vmax is dependent on enzyme 
concentration, the Vmax was scaled according to the number of transfected cells used in the 
HEK293 ratio experiments described in section 2.2.4. In other words the Vmax value for AKR1C3 
and 17βHSD2 was calculated for each ratio depending on the number of transfected cells present 
per ratio (table 3.4). The resulting model was then used to predict the metabolism of 0.1 μM A4 or 
11KA4. 
 




Vmax, app values of AKR1C3:17βHSD2 ratios (µmol/hour) 
1:0 1:1 3:1 4:1 5:1 6:1 
AKR1C3* 
A4 1.11 0.012042 0.012042 0.036126 0.048168 0.060210 0.072252 
11KA4 2.87 0.148860 0.148860 0.446580 0.595440 0.744300 0.893160 
17βHSD2 T 3.35 0.000000 1.886400 1.886400 1.886400 1.886400 1.886400 
11KT 5.84 0.000000 2.062800 2.062800 2.062800 2.062800 2.062800 
 
 
The resulting model, as seen in figure 3.12, predicted that an AKR1C3:17βHSD2 ratio of 1:0 (only 
AKR1C3) would slowly convert A4 to T, with 20% conversion being achieved after 24 hours. In 
contrast, the model predicted that 11KA4 would rapidly be converted to 11KT with 70% conversion 
*unpublished data from a separate study in our group. 
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being achieved after 24 hours. The inclusion of 17βHSD2 resulted in a steady state being reached 
for all ratios and both substrates. Increased AKR1C3:17βHSD2 ratios had little effect on the 
metabolism of A4 to T and the maximum conversion of A4 to T at steady state was only 10%. In 
contrast, increased AKR1C3:17βHSD2 ratios significantly shifted the steady state from 10% 11KT 















3.4.3. AKR1C3:17βHSD2 ratios in PC3 cells 
The androgen independent PCa cell line, PC3, endogenously expresses 17βHSD2, but does not 
express AKR1C3 (155). This cell line was therefore used to further investigate the effect of 
AKR1C3:17βHSD2 ratios on the metabolism of A4 and 11KA4 by transiently transfecting the cells 
with increasing concentrations of AKR1C3. The cells were incubated with 0.1 µM A4 or 11KA4 in 
the presence of 10 µM of the SRD5A inhibitor, dutasteride, which was included to prevent the 
downstream metabolism of either the substrates or products. The levels of 17βHSD2 and AKR1C3 
were confirmed by qPCR.  
Results showed that the expression of endogenous 17βHSD2 remained constant (figure 3.13A). 
The expression of AKR1C3 was low in control samples (pCINeo transfected cells), but increased 
significantly after transfection. Furthermore, the levels of AKR1C3 increased proportionally (2-fold) 
when 0.25, 0.5 or 1 µg AKR1C3 plasmid DNA was added (figure 3.13B).  
A) B) 
Figure 3.12: A model used to predict the metabolism of (A) A4, and (B) 11KA4 by increasing AKR1C3:17βHSD2 
ratios. The model was constructed by Prof JL Snoep, Biochemistry department, Stellenbosch University. 
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The metabolism of A4 and 11KA4 in PC3 cells transfected with increasing concentrations of 
AKR1C3 was found to mirror the results of the HEK293 ratio experiments described above (section 
3.4.1). Only very low levels of A4 were converted to T under all conditions, while the amount of 
11KT produced increased significantly when the cells were transfected with 0.5 and 1 μg AKR1C3 
(figure 3.14). 
Figure 3.13: qPCR analysis of (A) 17βHSD2 and (B) AKR1C3 in PC3 cells. Results are shown as means ± SEM of 
three independent experiments each performed in triplicate. Data from the individual experiments was normalized using 
log transformation and mean centering prior to analysis (154). Statistically significant differences are indicated by *, ** or 







































































Figure 3.14: The metabolism of 0.1 µM A4 (A) and 11KA4 (B) by PC3 cells transfected with increasing amounts of 
AKR1C3. Steroids were extracted after 24 hours and analysed using UPC
2
-MS/MS. Results are shown as means ± SEM 
of three independent experiments each performed in triplicate. Letters a, b, c and d represents significant differences 
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It should be noted that these experiments were conducted in the presence of the SRD5A inhibitor, 
dutasteride, which was added to prevent downstream metabolism of the substrates and products. 
We therefore confirmed that dutasteride has no effect on the activity of either 17βHSD2 or 
AKR1C3 by assaying the conversion of T and 11KT or A4 and 11KA4 in HEK293 cells transiently 
transfected with either enzyme, respectively, in both the presence and absence of 10 µM 
dutasteride (figure 3.15 and 3.16). No significant differences were observed between control 
samples and those treated with dutasteride, thereby confirming that this SRD5A inhibitor has no 
significant effect on the activity of AKR1C3 or 17βHSD2. Thus results obtained from the 






Figure 3.15: The effect of dutasteride on 17βHSD2 activity. Initial rates for the conversion of (A & B) 0.1 µM and (C & 
D) 1 µM T and 11KT in the presence and absence of 10 µM dutasteride by HEK293 cells expressing 17βHSD2. Steroids 
were extracted and measured by UPC2-MS/MS.  Linear regression lines were fitted in GraphPad Prism. The results are 
from a single experiment performed in triplicate and are expressed as the mean ± SD. 
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3.5. The metabolism of T and 11KT in PCa cell lines endogenously expressing 
AKR1C3 and 17βHSD2. 
 
Three PCa cell lines were chosen to validate the results obtained by the ratio experiments 
described above (sections 3.4.1 and 3.4.2) by investigating the effect of endogenous AKR1C3 and 
17βHSD2 activity on the metabolism of A4, T, 11KA4 and 11KT. 
LNCaP cells were originally derived from a needle biopsy taken from the left supraclavicular lymph 
node of a 50-year old Caucasian male (156). LNCaP cells are relatively slow growing cells, which 
express a mutated AR (T877A) and are androgen responsive. The cell line C4-2 (not included in 
this study) was derived from a tumour which developed in castrated nude mice injected with 
LNCaP cells. The C4-2B cell line was derived from a bone metastasis after the orthotopic 
transplant of the C4-2 cells in nude mice 5. C4-2B is thus a metastatic derivative of the LNCaP cell 
line and are considered to be a model of CRPC (157).  
The VCaP cell line was obtained from a patient who underwent androgen deprivation by groserelin 
acetate plus flutamide as well as three different regimens of chemotherapy. VCaPs are thus 
Figure 3.16: The effect of dutasteride on AKR1C3 activity. Initial rates for the conversion of (A & B) 0.1 µM and (C & 
D) 1 µM A4 and 11KA4 in the presence and absence of 10 µM dutasteride by HEK293 cells expressing AKR1C3. 
Steroids were extracted and measured by UPC2-MS/MS.  Linear regression lines were fitted in GraphPad Prism. The 
results are from a single experiment performed in triplicate and are expressed as the mean ± SD. 
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considered to be a model of CRPC. They are a slow growing cell line and overexpress the wild 
type AR.  
The levels of endogenous 17βHSD2 and AKR1C3 expression in VCaP, C42B and LNCaP cell 
lines were investigated using qPCR. No statistical significant difference was observed in the levels 
of 17βHSD2 expressed in the three cell lines although it appeared that LNCaP cells express higher 
levels of 17βHSD2 compared to the VCaP or C42B cells (figure 3.17A). The endogenous 
expression of AKRC3 was higher than that of 17βHSD2 in all three cell lines. Significantly higher 
levels of AKR1C3 were observed in VCaP cells when compared to C42B and LNCaP cells (figure 
3.17B). 
The ratio of AKR1C3 to 17βHSD2 expression in each cell line was subsequently calculated. The 
results showed that VCaP cells have a significantly higher ratio of AKR1C3 to 17βHSD2 compared 
to C42B and LNCaP cells. No significant difference in the ratio of AKR1C3 to 17βHSD2 was 
observed between C42B cells and LNCaP cells (figure 3.18). 
 
The cells were subsequently all incubated with 0.1 µM of each substrate (A4, 11KA4, T and 11KT) 
in the presence of dutasteride to inhibit the downstream metabolism of substrates or products. 
Time points where collected every 24 hours for a period of 4 days. As expected significantly higher 
rates of conversion were observed for 11KA4 when compared to A4 in all three cell lines. Overall 
















































































Figure 3.17: qPCR analysis of (A) 17βHSD2 and (B) AKR1C3 expression VCaP, C42B and LNCaP cells. Results 
are shown as means ± SEM of three independent experiments each performed in triplicate. Statistically significant 
differences are indicated by *, ** or *** for p<0.05, p<0.01 or p<0.001, respectively. 
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that these cells express the highest levels of AKR1C3 and had the highest ratio of AKR1C3 to 
17βHSD2 (figure 3.18). After 96 hours only 12% A4 was converted to T, while 80% 11KA4 was 
converted to 11KT during the same time the same time (figure 3.19). Interestingly, although VCaP 
cells express only low levels of 17βHSD2, T was efficiently converted to A4 when added as a 
substrate (88% metabolised after 96 hours). In contrast, only low levels of 11KA4 were produced 
when 11KT was added as a substrate (14% metabolised after 96 hours) (figure 3.19). While these 
conversions are likely due to 17βHSD2, the potential role of other oxidative 17βHSD cannot be 
















The conversion of A4 and 11KA4 to T and 11KT, respectively, were substantially lower in C4-2B 
and LNCaP cells, which both express significantly less AKR1C3 than VCaP cells. Nevertheless, 
the same trend was observed with both cell lines showing a preference for the conversion of 
11KA4 (figure 3.19). Similar to the results in the VCaP cells, when T and 11KT were given as 
substrates a preference was observed for the conversion of T in both C4-2B and LNCaP cells. Also 
it is interesting to note that the highest level of conversion from 11KT to 11KA4 was observed in 
LNCaP cells (figure 3.19) which correlates to the observation that this cell line expresses the 











































Figure 3.18: qPCR analysis of the endogenous 
expression of AKR1C3:17βHSD2 in VCaP, C42B and 
LNCaP cell lines. Results are shown as means ± SEM of 
three independent experiments performed in triplicate (n=3). 
Statistically significant differences are indicated by *, ** or *** 
for p<0.05, p<0.01 or p<0.001, respectively. 
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Figure 3.19: The metabolism of 0.1 µM A4, 11KA4, T and 11KT by VCaP, C42B and LNCaP cells in the presence of 
dutasteride. Steroids were extracted and analyzed using UPC
2
-MS/MS. Results are shown as means ± SEM of two 
independent experiments each performed in triplicate. Statistically significant differences are indicated by *, ** or *** for 
p<0.05, p<0.01 or p<0.001, respectively. 
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PCa is a hormone dependent cancer. ADT is therefore used to treat the advanced stages of this 
disease and is accomplished through either chemical or physical castration (27).  While ADT 
initially yields excellent results, in many cases the PCa later returns despite the castrate levels of T 
and is then known as CRPC (42). Although CRPC was initially thought to be androgen 
independent, many recent studies have shown that in the majority of cases this is in fact not true 
(57, 74). Instead CRPC is fuelled by androgen precursors of adrenal origin. CRPC tissue has been 
shown to convert the androgen precursors DHEA and A4 to the potent androgen DHT via the 
alternate 5α-dione pathway (158). Our laboratory has also recently suggested that the 
intratumoural conversion of the adrenal steroid 11OHA4 to the potent androgens 11KT and 
11KDHT may contribute to the development and maintenance of CRPC (107, 115). Both the 5α-
dione and 11OHA4 pathways rely on the activity of key steroidogenic enzymes, the majority of 
which are shared by both pathways. Consequently, the study and characterization of these 
enzymes is vital for our understanding of disease development and progression and may even 
lead to new targets being identified for drug development.  
Many of the key steps in intratumoural androgen metabolism are catalysed by 17βHSD enzymes. 
For the most part C19 steroids with a keto group at carbon 19 have little to no androgenic activity, 
while C19 steroids with a beta hydroxyl group at this position are androgenic. The enzyme 
AKR1C3 (17βHSD5) catalyses the conversion of inactive 17-keto C19 steroids to the more active 
17β-hydroxy C19 steroids, while the reverse reaction is catalysed by 17βHSD2. Together these 
enzymes therefore play a vital role in regulating the intratumoural pool of active androgens. 
Numerous studies have shown that the expression levels of these enzymes are altered during the 
development of CRPC (112, 121–123, 126). A significant increase in the expression of AKR1C3 
has been observed (124, 149), while the levels of 17βHSD2 appear to remain constant or 
decrease (127, 150). A study by Stanbrough et al. (121) found that AKR1C3 is the most 
upregulated enzyme which is involved in androgen biosynthesis in CRPC patients at both RNA and 
protein levels within tumour and soft tissue metastasis. Using microarrays, they found a 5.3 fold 
increase in the expression of AKR1C3 in CRPC. Immunohistochemical analysis showed that only 
5.6% of primary tumours stained strongly for AKR1C3 compared to the 58% of CRPC samples. It 
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has thus been suggested that this phenomenon acts as a mechanism to compensate for the 
reduced levels of androgens observed after ADT. 
Although both AKR1C3 and 17βHSD2 have been well characterized using classical substrates 
such as those found in the 5α-dione pathway, the activity of these enzymes towards metabolites 
from the novel 11OHA4 pathway has not yet been investigated. Furthermore, the relative 
contribution of these enzymes to the 5α-dione and 11OHA4 pathways is unknown. The 
comprehensive characterization of these enzymes will therefore not only elucidate the activity of 
the individual enzymes, but will also provide a better understanding of intratumoural androgen 
metabolism. 
 
The characterization of 17βHSD2 activity towards 11-oxygenated substrates 
The activity of 17βHSD2 towards the 11-oxygenated substrates 11KT and 11KDHT as well as 
classical substrates T, DHT and 5α-adiol was characterized in this study. Interestingly although not 
statistically significant, 17βHSD2 tended to have slightly higher affinity for the classical substrates: 
DHT (Km, app
. = 3.18 ± 0.48 µM), T (Km, app = 3.35 ± 0.81 µM) and 5α-adiol (Km, app = 3.39 ± 0.94 µM) 
than for the 11-oxygenated substrates: 11KDHT (Km, app
. = 20.46 ± 3.56 µM) and 11KT (Km, app = 
5.48 ± 1.13 µM). Our results agree with previous studies by Wu et al. (143) and Lu et al. (159) 
which both showed that 17βHSD2 has a higher affinity for DHT than T. However, the Km values 
obtained by these previous studies were up to 10-fold lower that the values obtained in this study. 
Wu et al. (143) measured Km, app
 values of 0.31 μM and 0.39 μM for DHT and T, respectively, while 
the values determined by Lu et al. (159) were 0.25 μM and 0.61 μM for DHT and T, respectively. 
Differences in Km and Vmax values between this study and those of previous studies can be 
attributed to the differences in experimental procedure. The current study was conducted in vitro 
using HEK293 cells transiently transfected to express 17βHSD2, while Wu et al. assayed 
17βHSD2 activity using homogenates from transfected cells and added the cofactor NAD+ to 
initiate the reaction. Similarly, the experiments conducted by Lu et al. also made use of 
homogenates and added cofactor (NAD+). The current study forms part of a larger study which 
aims to characterise all the relevant androgen metabolizing enzymes in CRPC under cellular 
conditions and thus did not make use of additional cofactors, but instead relied on intracellular 
cofactor concentrations. In this study cells were first plated in 75 cm2 flasks, transfected and then 
detached and mixed prior to replating in 48 well plates, thus ensuring the equal distribution of 
transfected cells. All kinetic studies were thus conducted in cells expressing the same amount of 
17βHSD2 therefore allowing for the comparison of the determined kinetic constants.  
It was interesting to note that the affinity of 17βHSD2 for the 11-oxygenated substrate, 11KT (Km, 
app = 5.84 ± 1.13 µM) was lower than that of the classical substrates described above although no 
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statistical significance was found for results. While the affinity of 17βHSD2 for 11KDHT (Km, app = 
20.46 ± 3.56 µM) was even lower than that of 11KT, the accuracy of this parameter needs to be 
confirmed when commercial standards become available for the product 11K-5α-dione. The 
substrate 11K-5α-adiol was not commercially available for purchase and thus was not included in 
this study. 
The Vmax, app values for T, 5α-dione and 11KT were similar (ranging from 131 ± 9.52 to 143 ± 10.2 
µmol/hour/mg protein) while that of DHT was lower (140 ± 6.26 µmol/hour/mg protein) and that of 
11KDHT was higher (491  ±  50.7 µmol/hour/mg protein) as seen in table 3.3.  
Catalytic efficiency, defined as Kcat/Km, is perhaps the most appropriate way to compare the activity 
of an enzyme towards different substrates (160). The determination of Kcat is however dependent 
on the enzyme concentration being determined, which was not possible in this study as 17βHSD2 
was expressed in mammalian cells and protein determinations thus reflected the total protein 
content of the cells. The ratio of Vmax/Km could however be used to estimate the catalytic efficiency. 
This was possible as the Km and Vmax for all substrates were determined during the same 
experiment using methodology which ensured that the concentration of 17βHSD2 was constant as 
described above. The resulting estimated catalytic efficiencies (Vmax/Km) revealed that the preferred 
substrates were T (Vmax/Km = 39.1) and 5α-adiol (Vmax/Km = 40.1). Interestingly, estimated catalytic 
efficiencies for 11KT (Vmax/Km = 26.1), DHT (Vmax/Km = 27.5) and 11KDHT (Vmax/Km = 24.0) were all 
similar.  
Taken together this data showed for the first time that 17βHSD2 efficiently catalyses the 
conversion of 11-oxygenated C19 steroids from the 11OHA4 pathway, albeit less efficiently than 
some of the classical substrates.  
 
The effect of different AKR1C3:17βHSD2 ratios on the metabolism of T and 11KT  
The focus of this study was to compare the effect of different AKR1C3:17βHSD2 ratios on the flux 
through the alternate 5α-dione and 11OHA4 pathways. One substrate was thus selected for each 
of the pathways. 11KA4 was selected in the case of the 11OHA4 pathway as unpublished data 
from our group has demonstrated that the flux through the pathways results in the production of 
11KA4, which is further metabolized by AKR1C3 yielding 11KT. Although the flux through the 
alternate 5α-dione pathway bypasses the conversion of A4 to T by AKR1C3, and instead follows 
the 5α-reduction of A4 to 5α-dione prior to the conversion of 5α-dione to DHT by AKR1C3, A4 was 
selected as the representative substrate for the experiments conducted in this study for the 
following reasons. First, unpublished data from our group has shown that the affinity and catalytic 
efficiency of AKR1C3 towards A4 and 5α-dione is comparable, while this study has shown that the 
affinity and catalytic efficiency of 17βHSD2 were similar for T and DHT. Second, the downstream 
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metabolism of A4, T, 11KA4 and 11KT by SRD5A1 in PCa cell lines can be inhibited using an 
SRD5A inhibitor such as dustasteride, thus permitting only the conversion of these steroids by the 
17βHSD enzymes to be measured, while not affecting the activity of AKR1C3 or 17βHSD2. In 
contrast, both DHT and 5α-dione can be subjected to metabolism which cannot be blocked due to 
a lack of specific inhibitors for AKR1C2, which catalyses the 3α-reduction of these steroids. AKR 
inhibitors would lead to the inhibition of isozyme AKR1C3, which would compromise the results of 
this study. Third, the lower limits of detection of the UPC2-MS/MS method employed in this study 
were significantly lower for A4 and T than 5α-dione and DHT, as Δ4-steroids ionize better than 5α-
reduced steroids. Finally, experiments which did include both A4 and 5α-dione as substrates 
yielded nearly identical results, thus validating the use of A4 instead of 5α-dione (figure 3.9B).    
Three different systems were used to compare the effect of AKR1C3:17βHSD2 ratios on the 
metabolism of A4 and 11KA4 to T and 11KT, respectively. First, HEK293 cells, which do not 
endogenously express either AKR1C3 or 17βHSD2, were transfected individually with both 
enzymes after which the transfected cells were mixed to obtain different AKR1C3:17βHSD2 ratios. 
Second, PC3 cells, which endogenously express 17βHSD2, were transfected with increasing 
amounts of AKR1C3 to obtain different AKR1C3:17βHSD2 ratios. Lastly, the PCa cell lines, VCaP, 
C4-2B and LNCaP, were also used as in vitro model systems as all three cell lines endogenously 
express both enzymes, but at different ratios.  
The results from both the ratio experiments performed in the HEK293 cells (figure 3.9) and PC3 
cells (figure 3.14) were similar. In both systems the conversion of 11KA4 to 11KT increased 
significantly as the ratio of AKR1C3:17βHSD2 increased, while the conversion of A4 to T remained 
unchanged. The same results were observed irrespective of substrate concentration (0.1 μM or 1 
μM), as seen in figures 3.9 and 3.8 and whether the substrates were added individually or in 
combination (figure 3.11). These results were then confirmed in three PCa cell lines expressing 
different ratios of AKR1C3:17βHSD2 (figure 3.18). 11KA4 was converted to 11KT significantly 
faster than A4 was converted to T in each cell line. What‟s more the rate of conversion correlated 
well with the AKR1C3:17βHSD2 ratios determined by qPCR. For example, the conversion of 
11KA4 to 11KT was the fastest in the VCaP cell line which was shown to express the highest 
AKR1C3:17βHSD2 ratio (figure 3.18). 11KT was also metabolized to 11KA4 at a lower rate than T 
was metabolized to A4 in all three cell lines when 11KT and T were used as substrates (figure 
3.19). This was not unexpected as AKR1C3 converts 11-keto substrates more efficiently than 
classical substrates. Thus, the conversion from 11KT to 11KA4 by 17βHSD2 is countered by the 
highly efficient conversion from 11KA4 back to 11KT. Also, the conversion of 11-keto substrates by 
17βHSD2 is less efficient than the conversion of substrates from the classical pathway (table 3.3).  
A mathematical model was also constructed to predict the metabolism of A4 and 11KA4 in the 
presence of increasing AKR1C3:17βHSD2 ratios. The model predicted that the co-expression of 
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AKR1C3 and 17βHSD2 would lead to the establishment of a steady state where the rate catalysed 
by each enzyme is equal. The predicted steady states for the conversion of A4 to T ranged from ± 
1% T (1:1 ratio) to ± 10% T (6:1 ratio) (figure 3.12). In contrast the predicted steady states for the 
conversion of 11KA4 to 11KT ranged from ± 12% 11KT (1:1 ratio) to ± 45% 11KT (6:1 ratio) (figure 
3.12) thus confirming what was observed experimentally (figures 3.9A and 3.9C). The model 
clearly demonstrates that the increased AKR1C3:17βHSD2 ratios have a substantially greater 
effect on the conversion of 11KA4 than A4.  
This can be explained by the observation that AKR1C3 is significantly more efficient at catalysing 
the conversion of 11KA4 to 11KT than A4 to T (unpublished data) and the effect is confounded by 
the activity of 17βHSD2. The catalytic efficiency of AKR1C3 for the conversion of 11KA4 to 11KT is 
similar to that of the catalytic efficiency of 17βHSD2 for the conversion of 11KT to 11KA4. Thus, 
changes in the ratios of the enzymes will have significant effects on the flux. In contrast, the 
catalytic efficiency for 17βHSD2 for T is substantially higher that of AKR1C3 for A4 and as a result 
elevated levels of AKR1C3 has a minimal effect on the conversion of A4 to T due to the rapid 
conversion of T back to A4 by 17βHSD2. Elevate AKR1C3 levels alone may therefore not be 
sufficient to increase the flux through the 5α-dione pathway as was previously suggested.  
Taken together these results show that the upregulation of AKR1C3 observed in CRPC may have 
less of an effect on the 5α-dione pathway, but may favour the production of more potent androgens 
by the 11OHA4 pathway. Furthermore, these results show for the first time that 17βHSD2 
expression may play a vital role in regulating intratumoral androgen production in CRPC.     
 
Implications for CRPC 
To date the alternate 5α-dione pathway is believed to make the biggest contribution to the 
maintenance of the intratumoural androgen pool which drives the development and progression of 
CRPC. Previous studies by our group have, however, suggested that the overlooked 11OHA4 
pathway, which results in the production of the potent androgens 11KT and 11KDHT, may play a 
previously unrecognized role in the maintenance of intratumoural androgen levels.  
While more work is required to elucidate the role of the 11OHA4 pathway in the development and 
progression of CRPC the current study provides further evidence of the importance of this 
pathway. The most striking finding was that while altered enzyme expression of AKR1C3 and 
17βHSD2 is believed to facilitate the production of T and DHT this was not observed in any of the 
models employed in this study suggesting that the alternative 5α-dione pathway as well as the 
classical pathway may not be the main contributors to the pool of potent androgens after ADT as 
previously assumed. Conversely, significant increases in the conversion of 11KA4 to 11KT were 
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observed in all models used in this study to investigate the effect of altered AKR1C3:17βHSD2 
ratios. 
It should, however, be noted that in the classical and alternative 5α-dione pathways, the precursor 
androgen A4 is converted to DHT either via the production of T or 5α-dione and thus requires two 
enzymatic steps catalysed by SRDA1 and AKR1C3. In contrast an extra step is required in the 
11OHA4 pathway as 11OHA4 first needs to be converted to 11KA4 by 11βHSD2 before the latter 
can be converted to 11KT by AKR1C3 and the 11KDHT by SRD5A1. This step is necessary as our 
group has shown that neither AKR1C3 nor 17βHSD3 can catalyse the conversion of 11OHA4 to 
11OHT ((113), unpublished data). Even so, preliminary data from our group has shown that the 
initial conversion of 11OHA4 to 11KA4 is highly efficient and thus should not limit the flux through 
the 11OHA4 pathway. Also it is interesting to note that the adrenal produces higher levels of 
11OHA4 compared to A4 under both normal and ACTH-stimulated conditions (106, 107) and more 
substrate could therefore be available for the 11OHA4 pathway. Both DHEAS and DHEA can also 
be used as substrates for the alternate 5α-dione pathway, but both first need to be converted to A4 
(16).  
 
It is also interesting to note that while this study showed that 11KT production is favoured by 
AKR1C3, with seemingly minimal conversion back to 11KA4 by 17βHSD2, a previous study by our 
group has shown that 11KT and 11KDHT are metabolized and inactivated by downstream 
pathways at a significantly lower rate when compared to T and DHT (115). Taken together this 
data seems to indicate that the production of potent 11-oxygenated androgens is favoured by the 
upregulation of AKR1C3, and that the resulting 11-oxygenated androgens are inactivated at a low 
rate, thus suggesting that these steroids could accumulate in CRPC tissue. Indeed, a recent study 
has shown that 11-oxygenated metabolites are much more abundant in PCa tissue compared to 
metabolites from the classical pathway. Du Toit et al. (161) quantified androgens from PCa tissue 
samples collected from two patients, one who underwent no prior treatment; and one who 
underwent treatment with an androgen antagonist. The precursor 11OHA4 was found to be the 
most prominent steroid in both patients followed by 11KT in the patient who underwent treatment 
with an androgen antagonist. The potent androgen 11KDHT was found to be 7-fold and 9-fold 
higher compared to DHT levels in each patient, respectively, thus highlighting that the 11-
oxygenated steroids may accumulate.  
 
AKR1C3 as a possible drug target 
The increased AKR1C3 expression found in CRPC has made this enzyme a target for the 
development of a therapeutic drug for the treatment of CRPC. A number of studies collectively 
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conclude that AKR1C3 plays a central role in intratumoural androgen metabolism leading to the 
production of potent androgens from adrenal androgen precursors which drives AR-regulated gene 
expression and cell growth despite castrate levels of T (66, 79, 124, 139, 162, 163). During their 
research into the alternate 5α-dione pathway Chang et al. (111) showed that the conversion of A4 
to 5α-dione by SRD5A1 was rapid while the conversion of the latter to DHT was slow, thus leading 
to the hypothesis that AKR1C3 catalysis the rate-determining step and thus making AKR1C3 a 
good drug target. Data from this study highlights the importance of AKR1C3 in the 11OHA4 
pathway. Inhibiting AKR1C3 could therefore inhibit both pathways, thereby significantly reducing 
intratumoural androgen levels.   
Currently two approved CRPC drugs include abiraterone which inhibits CYP17A1 and 
enzalutamide which is a synthetic non-steroidal antiandrogen and competitively inhibits androgen 
binding to androgen receptors and prevents the translocation of the androgen receptor to the 
nucleus. The inhibition of CYP17A1 by abiraterone prevents the production of all androgens and 
androgen precursors, but also inhibits the production of other important steroid hormones like the 
glucocorticoid cortisol. Abiraterone treatments therefore have side effects which need to be 
countered by glucocorticoid treatment. Conversely, an AKR1C3 inhibitor is predicted to have fewer 
side effects because it acts further downstream. The use of enzalutamide therapy often leads to 
acquired resistance against this drug. In a study by Lui et al. (164) they developed an 
enzalutamide-resistant PCa cell line to further investigate this phenomenon. Interestingly they 
found that AKR1C3 expression is upregulated in the enzalutamide-resistant PCa cells. 
Furthermore, AKR1C3 was highly expressed in enzalutamide-resistant prostate xenograft tumours. 
Knockdown or inhibition of AKR1C3 resensitized enzalutamide-resistant PCa cells to enzalutamide 
treatment both in vitro and in vivo. These results therefore demonstrate that an AKR1C3 inhibitor 
may counter the resistance to enzalutamide. The development of an AKR1C3 inhibitor is however 
a complex task as AKR1C3, AKR1C1, AKR1C2 and AKR1C4 share 84% sequence homology. The 
drug would therefore need to be highly specific as all these enzymes plays a role in steroid 
metabolism and off target effects may lead to unwanted side effects.  
 
Future studies 
This study has added to the growing body of evidence showing that the 11OHA4 pathway may 
play an important role in the development and progression of CRPC. Further studies are however 
required to confirm this. An ongoing project in our laboratory is to characterize all enzymes 
responsible for metabolism in the 11OHA4 pathway and to build a comprehensive model of 
intratumoural androgen metabolism. In addition, it is vital that the levels of the 11OHA4 metabolites 
in PCa and CRPC tissue are determined and compared to that of the classical androgens. This 
can then be linked to altered enzyme expression also investigated in this tissue. The results from 
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this study strongly suggest that it would be useful to investigate AKR1C3 inhibitors in the treatment 
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